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A B S T R A C T
Background
Ischaemic heart disease (IHD) is amajor cause of mortality andmorbidity and its prevalence is set to increase. Secondary prevention aims
to prevent subsequent acute events in people with established IHD. While the benefits of individual medical and lifestyle interventions
is established, the effectiveness of interventions which seek to improve the way secondary preventive care is delivered in primary care
or community settings is less so.
Objectives
To assess the effectiveness of service organisation interventions, identifying which types and elements of service change are associated
with most improvement in clinician and patient adherence to secondary prevention recommendations relating to risk factor levels and
monitoring (blood pressure, cholesterol and lifestyle factors such as diet, exercise, smoking and obesity) and appropriate prophylactic
medication.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2007, Issue 4), MEDLINE (1966
to Feb 2008), EMBASE (1980 to Feb 2008), and CINAHL (1981 to Feb 2008). Bibliographies were checked. No language restrictions
were applied.
Selection criteria
Randomised or quasi-randomised controlled trials of service organisation interventions in primary care or community settings in
populations with established IHD.
Data collection and analysis
Analyses were conducted according to Cochrane recommendations and Odds Ratios (with 95% confidence intervals) reported for
dichotomous outcomes, mean differences (with 95% CIs) for continuous outcomes.
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Main results
Eleven studies involving 12,074 people with IHD were included. Increased proportions of patients with total cholesterol levels within
recommended levels at 12 months, OR 1.90 (1.04 to 3.48), were associated with interventions that included regular planned appoint-
ments, patient education and structured monitoring of medication and risk factors, but significant heterogeneity was apparent. Results
relating to blood pressure within target levels bordered on statistical significance. There were no significant effects of interventions on
mean blood pressure or cholesterol levels, prescribing, smoking status or body mass index. Few data were available on the effect on
diet. There was some suggestion of a “ceiling effect” whereby interventions have a diminishing beneficial effect once certain levels of
risk factor management are reached.
Authors’ conclusions
There is weak evidence that regular planned recall of patients for appointments, structured monitoring of risk factors and prescribing,
and education for patients can be effective in increasing the proportions of patients within target levels for cholesterol control and
blood pressure. Further research in this area would benefit from greater standardisation of the outcomes measured.
P L A I N L A N G U A G E S U M M A R Y
Organising preventive care in community settings for people with heart disease
Ischaemic heart disease is the term used for conditions caused by a narrowing of the arteries that supply blood to the heart muscle.
Patients may have angina, or may have had a previous myocardial infarction (heart attack) or surgery to widen or bypass the affected
arteries. “Secondary prevention” is the term used to describe health care that aims to prevent further events or the worsening of such
conditions in these patients.
Research has been done to try to find the best way to organise health care so that people with heart disease benefit most from lifestyle
changes and medications that are known to help to reduce the risk of heart disease getting worse.
This research suggests that careful changes in the way health care and advice are provided may increase the proportion of patients whose
total cholesterol levels and blood pressure are within target levels, but the evidence is weak. No evidence was found that suggested
similar changes can help to reduce other risk factors or improve the prescribing of medicines that can prevent further disease. The
changes that appear to be more effective include regular planned appointments with a clinician, careful monitoring of medications
and risk factors (such as blood pressure, cholesterol and lifestyle), and education for patients to raise awareness of the importance of
secondary prevention.
B A C K G R O U N D
Ischaemic heart disease - burden of disease
Ischaemic heart disease (IHD) is a major cause of mortality and
morbidity and is a growing problem: worldwide it is estimated that
some 50 million people have existing IHD (Neal 2004) with a one
in four (25%) risk of suffering a further serious event in the next 10
years (Law 2002; WHO 2002). Although in recent decades IHD
mortality rates have fallen in many developed countries, rates of
morbidity are increasing as a result of improveddiagnosis andmore
successful treatment of acute illness which, for example, has led to
an increasing number of survivors of myocardial infarction (HDA
2000; Law 2002; Neal 2004; NSF 2000; SIGN 2000). Another
major factor affecting increased prevalence of IHD morbidity is
the growing elderly population in many countries. Age plays a
major role in IHD: the prevalence of angina in particular rises
sharply with age (Task Force 1997); the incidence of myocardial
infarction also increases with age and varies between geographical
regions (HDA 2000).
Secondary prevention of IHD
The primary prevention of IHD is desirable and is considered to
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be most appropriately targeted in the first instance at those con-
sidered to be at a high risk of developing IHD because of com-
binations of risk factors - including smoking, raised blood pres-
sure and serum cholesterol levels, family history of IHD, obesity
and diabetes (De Backer 2003; Wood 1998a). However, multi-
factorial interventions aimed at primary prevention and delivered
at individual patient level appear to offer only modest benefit in
terms of risk factor reduction, so that their clinical- and cost-ef-
fectiveness is still a matter for debate (Ebrahim 2006).
Secondary prevention (the prevention of further acute IHD events
amongst those with established IHD) is more easily targeted, is
widely advocated and is considered a priority in countries with
high prevalence of IHD (DoHC Ireland 1999;HDA2000;Moher
1997; NSF 2000; SIGN 2000; Wood 1998a; Wood 1998b). Sec-
ondary prevention of IHD potentially comprises both patient-
and clinician-centred activities aimed at reducing risk of further
IHD events through effective management of modifiable clinical
risk factors:
• patient education and motivation in relation to healthy
lifestyle choices - smoking cessation, healthy diet and regular
exercise;
• effective monitoring of patients’ risk and prophylactic use
of appropriate medications - antiplatelets, beta blockers,
angiotensin converting enzyme (ACE) inhibitors, statins,
angiotensin II receptor blockers, calcium channel blockers (De
Backer 2003).
In a recent meta-analysis, secondary preventive programmes that
include risk factor education or counselling and structured ex-
ercise were associated with a significantly reduced risk of subse-
quent acute myocardial infarction (0.62 (CI 0.44 to 0.87)). Pro-
grammes including risk factor education or counselling but no
exercise component were associated with a significantly reduced
risk of mortality (risk ratio, 0.87 (CI 0.76 to 0.99)). Programmes
that are purely exercise-based were associated with a significantly
reduced risk of mortality (risk ratio, 0.72 (CI, 0.54 to 0.95)).
Most programmes were associated with small improvements in
quality of life and functional status (Clark 2005). Broader in-
terventions focusing on wider lifestyle modification, risk factor
monitoring and management and prophylactic medication have
shown some improvements in health status and in terms of lev-
els of risk factor monitoring and prescribing (Campbell 1998;
Kiessling 2002; Munoz 2007). However, questions regarding the
optimal design, frequency and duration of interventions remain
unanswered (McAlister 2001).
Whilst the effectiveness of secondary preventivemeasures is in little
doubt, their use has been found to be suboptimal (Bowker 1996;
Brady 2001;Campbell 1998a;Campbell 1998b;Campbell 1998c;
Carroll 2003; Cupples 1994; Cupples 1999; Flanagan 1999; Jolly
1999; Moher 1995; Moher 2001; Ramsay 2006; Williams 2003).
Guideline recommended treatments and secondary prevention
programmes have been found to be underused in women and
older people with IHD, whilst those in lower socioeconomic strata
have been found to be more likely to have angina but less likely
to consult their doctor (Buckley 2007; Murphy 2006). Compared
with those who have had an acute myocardial infarction, patients
with angina alone appear less likely to receive appropriate sec-
ondary preventive care (Buckley 2008). Poor detection and man-
agement of hypercholesterolaemia has been detected in IHD pa-
tients (Hickling 2005).
Although the content and aims of evidence-based guidelines on
the secondary prevention of IHD are supported by the majority of
primary care physicians, only a minority of such physicians believe
they are being implemented successfully. The reasons for this are
multi-factorial and are believed to include lack of clinician time,
poor patient compliance and the cost of prophylactic prescriptions
(Hickling 2005). Uncertainty regarding best practice in the deliv-
ery of secondary preventive care can only serve to perpetuate this
situation. Interventions to improve the uptake and implementa-
tion of practice guidelines in diverse clinical areas have included
individual and workshop outreach education for clinicians and
the involvement of clinical opinion leaders and many of these in-
terventions have improved practice to some extent, although in
general the effect has been small (Doumit 2007; Forsetlund 2009;
Hobbs 2002; Majumdar 2007; O’Brien 2007).
With the aim of informing practical and achievable planning in
primary care/community settings, this review is focused purely on
interventions that alter the way existing service in primary care
or community settings are organised with outcomes being patient
and clinician adherence to the recommendations of secondary pre-
ventive practice guidelines.
Service organisation interventions
For the purposes of the review, a service organisation intervention
for the secondary prevention of IHD is defined as an intervention
which comprises a systematic change, or changes, in the organisa-
tion of existing care provision targeting at least one of the follow-
ing:
a) improved levels of appropriate and available secondary preven-
tive medication and risk factor monitoring
b) improved patient adherence to medication
c) improved patient adherence to secondary prevention recom-
mendations relating to modifiable lifestyle factors.
Primary care/community settings
In countries in which the term is in use, primary care is the set-
ting in which most IHD is first detected and where its long term
management is conducted. In many other countries, even those
in which most diagnosis of IHD may take place in secondary care
settings, long term management of IHD is conducted in commu-
nity settings with occasional referral to specialist services.
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Primary care is described by Starfield as “that level of a health ser-
vice system that provides… person focused care over time… Pri-
mary care addresses the most common problems in the commu-
nity by providing preventive, curative and rehabilitative services
to maximize health and well being. It integrates care when there
is more than one health problem and deals with the context in
which illness exists and influences the responses of people to their
health problems. It is care … directed at promoting, maintaining,
and improving health” (Starfield 1998). By such definition pri-
mary care is ideally suited to the long-term healthcare interven-
tions which are needed to deliver secondary prevention of IHD at
community level.
In countries in which the term is in use, primary care is widely
understood as referring to those multidisciplinary health services
which provide the first point of access to healthcare services, are
designed to maintain a long term relationship with the patients,
families and communities and are based primarily in units of vary-
ing size and function within the community rather than in hospi-
tals. Primary care is not, however, a termwhich is in use universally
and so in this review the term “community settings” is also used
to highlight the fact that studies conducted in countries in which
primary care is not a commonly used term need not be excluded.
A systematic review will best be able to inform practice in pri-
mary care if it considers evidence generated within - or at least
principally within - primary care which relates to populations that
are broadly representative of the primary care IHD population.
There has been some debate about whether study populations
identified in secondary and tertiary care settings are representa-
tive of the community population of people with IHD as defined
in this review. It has been argued, for example, that populations
identified in secondary and tertiary care settings for angina studies
have been disproportionately white and male, mostly with previ-
ous acute myocardial infarction or coronary artery bypass graft or
percutaneous transluminal coronary angioplasty at a time when
angina is increasingly diagnosed in primary care in the absence of
such co-morbidity (Timmis 2007); and that participants in a high-
profile randomised controlled trial, which heavily influenced the
British Hypertension Society’s guidelines for the management of
blood pressure in post-stroke patients, were more likely to be male,
younger and hypertensive than the general practice population of
patients with previous stroke (Mant 2006).
O B J E C T I V E S
To determine the effectiveness of service organisation interven-
tions which are intended to improve secondary prevention of is-
chaemic heart disease and which are delivered in primary care and
community settings.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised trials, randomised by individual or by group (for ex-
ample, practice or family) conducted with appropriate ethical ap-
proval, blinded and un-blinded (given the nature of the interven-
tions under consideration, effective blinding may not be possible)
with at least one comparator (which may be a normal care control
arm or a distinct intervention) and an intervention duration of at
least 12 months.
Types of participants
For the purpose of this review, people have been considered to
have IHD if they have had a previous acute myocardial infarction,
previous revascularisation (coronary artery bypass grafting, per-
cutaneous transluminal coronary angioplasty or coronary artery
stent) in response to myocardial ischaemia, or who have angina. A
pragmatic approach has been taken to diagnostic standards which
reflects the clinical reality in community settings: diagnosis by
general practitioner or family physician and/or by objective tests
and/or by specialist physician opinion and/or by another health
care professional for the purposes of inclusion in a trial included
in the review.
Types of interventions
Service organisation interventions
This review considers service organisation interventions whose
main elements are specific planned changes in existing care provi-
sion in primary care and community settings and which are aimed
at improved patient and clinician adherence with recommenda-
tions on secondary prevention of IHD.
Primary care/community settings
For the purposes of this review, programmes have been considered
to have been delivered in primary care (or community settings)
if they have been delivered in contexts which fulfil the definition
of primary care established by the Committee on the Future of
Primary Care at the Institute of Medicine in the United States:
“Primary care is the provision of integrated, accessible healthcare
services by clinicians who are accountable for addressing a large
majority of personal healthcare needs, developing a sustained part-
nership with patients, and practicing in the context of family and
community” (Donaldson 1996).
Primary care clinicians are defined as “an individual who uses a rec-
ognized scientific knowledge base and has the authority to direct
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the provision of personal health services to patients” and are “gen-
erally considered to be physicians, nurse practitioners and physi-
cian assistants” and “a broader array of individuals in a primary
care team” (Donaldson 1996).
In the context of cardiovascular care, the primary care team may
include community-based physicians such as general practitioners
and family physicians, community pharmacists, practice nurses,
community and public health nurses and other professions allied
to medicine such as dieticians, occupational therapists and phys-
iotherapists.
• Studies have been included in the review if the
interventions have been delivered principally in primary care or
community settings by either primary care clinicians or clinicians
whose normal roles are in other areas within health systems -
including secondary care (e.g. community hospitals) and tertiary
care (e.g. general hospitals, medical centres and teaching
hospitals) - but who have worked in a primary care context for
the purposes of the programme’s delivery.
• Studies from countries where the primary care model is not
standard have been included if the studied care is delivered by
clinicians whose practice is accessible, involves ongoing and
long-term relationships with patients and provides for a wide
range of healthcare needs.
• Studies have not been included in the review if the
interventions have been delivered primarily through secondary
or tertiary care contexts by clinicians or teams of clinicians whose
relationship with patients is not long term or ongoing and who
do not provide for a wide range of healthcare needs.
Comparators
In the included studies, the comparators are “normal care”. Yet in
different health services and regions baseline levels of secondary
preventive care may differ markedly. Comparison of the effective-
ness of interventions in countries with different levels of develop-
ment may be methodologically uncertain: the effectiveness of in-
terventionsmay be affected by both the baseline levels of secondary
preventive care provision and by differing levels of underlying de-
ficiencies in health, access to health services, education, standards
of living and opportunity for healthy lifestyle. Baseline levels of
provision have been described in the review where appropriate in
order to inform interpretation and implementation of the results.
Where visual inspection of plots detects substantial heterogeneity,
sensitivity analysis has been used as appropriate to consider the
effect on outcomes of differing baseline service provision.
Types of outcome measures
Primary outcomes
1. Improved patient adherence to medication and to secondary
prevention recommendations relating to modifiable lifestyle fac-
tors (smoking, body mass index, exercise, diet).
2. Improved levels of prescribing of appropriate and available pro-
phylactic medication for IHD.
3. Improved risk factor monitoring (blood pressure, blood choles-
terol, smoking, body mass index, exercise, diet).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in The Cochrane Library (2007, Issue 4), MED-
LINE on Ovid (1966 to Feb 2008), EMBASE on Ovid (1980 to
Feb 2008), and CINAHL on EBSCO (1981 to Feb 2008). No
language or other limitations were imposed. Consideration was
given to variations in terms used and spellings of terms in different
countries so that studies were not missed by the search strategy
because of such variations.
We designed the search strategies in accordance with Cochrane
Heart Group methods and guidance. We developed a detailed
search strategy for each electronic database searched, based on the
strategy designed for CENTRAL but revised appropriately (see
Appendix 1).
Searching other resources
We searched the reference lists of all eligible trials and previous
systematic reviews for additional studies.
Data collection and analysis
Selection of studies
The main review author screened the titles of studies identified
by the search strategy and discarded the studies that were clearly
irrelevant. Two review authors then independently screened the
abstracts of retained studies for relevance and eligibility. We then
obtained the full text reports of all apparently potentially relevant
studies and assessed them independently for eligibility, based on
the defined inclusion criteria. It was agreed that disagreements be-
tween review authors would be resolved by discussion with the
other reviewers and unresolved issues referred to the coordinat-
ing editor of the Cochrane Heart Group. However this was not
necessary. Papers in languages other than English were assessed by
native speakers for eligibility and subsequently for data extraction.
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Data extraction and management
We extracted data onto standardised forms. Two review authors
independently extracted relevant data regarding inclusion criteria
(study design, participants, interventions, and outcomes), qual-
ity criteria (randomisation, blinding, and control) and results . In
cases where insufficient data were reported (e.g. method of ran-
domisation, statistical methods) we contacted study authors where
possible for further information. Excluded studies and reasons for
exclusion are detailed in the ’Characteristics of Excluded Studies’
table.
Assessment of risk of bias in included studies
Two review authors independently assessed the quality of eligible
trials. Factors considered included quality of random allocation
and concealment (where appropriate), description of drop-outs
and withdrawals and missing data, blinding during intervention
and at outcome assessment (where appropriate), description of and
protection against possible contamination (where appropriate),
publication bias and non-selective publication of results to protect
against reporting bias. It was agreed that disagreements between
reviewers would be resolved by discussion with the other reviewers
and unresolved issues referred to the coordinating editor of the
Cochrane Heart Group.
Data synthesis
Where appropriate and possible, we combined results from in-
cluded studies for each outcome to give an overall estimate of treat-
ment effect. For dichotomous variables we derived odds ratios and
95% confidence intervals (CI) for each outcome. For continuous
variables we calculated mean differences and 95%CI for each out-
come.
Given the diverse nature of the interventions, we recognised at
protocol stage that pooling of data may not be appropriate and
planned to present a narrative review of results of included studies
where this proved to be the case.
Where data from individually randomised trials were combined
with data from trials randomised at cluster level, we calculated
effective sample sizes for the cluster-randomised trials using the
approach described in the Cochrane Handbook for Systematic
Reviews of Interventions (Cochrane Handbook 2008). Using the
mean cluster size for each trial and intracluster correlation coef-
ficients, we calculated effective sample sizes that account for the
cluster design effect.
Where heterogeneity was detected, we used random effectsmodels
for analysis of pooled data.
Subgroup analysis and investigation of heterogeneity
We had envisaged that subgroup analysis may consider the dif-
ferent effects of interventions amongst different populations, in
different settings. No analyses contained sufficient trials to neces-
sitate this approach.
Sensitivity analysis
Where we identified heterogeneity in analyses, sensitivity analysis
considered the influence of individual studies that differed from
the rest in terms of factors such as gender, age bands, IHD di-
agnostic category (acute myocardial infarction, angina, previous
revascularisation), intervention delivery, baseline service provision
levels, setting and geographic region. This afforded an opportunity
to consider the robustness of the pooled results and also to try to
identify particular participant subgroups or component elements
of interventions for which results are significantly better or worse.
R E S U L T S
Description of studies
Selection of studies
Searching as per strategy identified 3396 titles. On review by the
authors, 65 of them appeared from title or abstract to meet the
inclusion criteria. Consideration of full text reports resulted in 49
of these being excluded for reasons specified in Characteristics of
excluded studies. Most commonly, papers were excluded because
of lack of randomisation or short study duration or because the
outcomes reported were not those considered by this review.
As anticipated at the protocol writing stage, we found heterogene-
ity in study settings, methods and intervention types. In addition,
differing health systems and concepts of general practice, primary
care, family or community medicine in different countries resulted
in challenges with regard to determining which studies might be
included and which excluded. With these challenges in mind we
endeavoured to state a priori definitions of concepts such as “ser-
vice organisation intervention” and “primary care setting”. This
caution proved well-founded. Whilst many dozens of studies ap-
peared from their abstracts to be potentially eligible for inclusion,
this number reduced dramatically when we applied the definitions
for eligible interventions and settings upon inspection of full text
reports.
Service organisation interventions were defined as interventions
which comprise systematic changes in existing care provision
aimed at improved adherence with recommendations on sec-
ondary prevention of IHD. Emphasis was placed on the princi-
ple that no additional services or therapies should be provided to
the patient - that any improved secondary prevention might be
attributed to the organisation of the services and therapies already
available. Many studies were excluded because the interventions
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clearly involved the introduction of treatment or service elements
for IHD patients which were entirely additional to existing ser-
vices rather than changes in the way pre-existing services were de-
livered or organised. An example is the provision of professionally
supervised exercise programmes in patients’ homes.
A great many studies, although ostensibly primary care based, con-
sidered secondary or tertiary care outreach interventions rather
than interventions aimed at reorganisation or improvement of ex-
isting primary care. These were often studies based in hospital out-
patient contexts, or in the community but conducted by hospital-
based staff without significant liaison with existing primary care
or community health services. In locations where well developed
primary care or community medicine systems were in place, such
interventions were excluded. Conversely, there were a number of
studies set in locationswhere primary care or communitymedicine
systems are not in place and where health services are primarily
hospital-based. In these circumstances trials of interventions con-
ducted by secondary or tertiary care clinicians were included pro-
vided they did not introduce therapies or services which were not
previously available to patients who sought them and provided
they sought to influence secondary prevention long after patients
left the acute setting and returned to the community.
Included studies
Eleven remaining studies involving 12,074 patients formed the ev-
idence base for this review (Bond 2007b; Campbell 1998; Cupples
1994a; Eccles 2002; Feder 1999; Gao 2007; Kiessling 2002;
Moher 2001a (GP led);Moher 2001b (nurse led); Munoz 2007;
SHIP 1999; SPHERE). One study had two intervention arms
(and one control) and is therefore analysed as two studies (Moher
2001a (GP led); Moher 2001b (nurse led)). Four studies recruited
patients with angina or previous acutemyocardial infarction, coro-
nary artery bypass graft, percutaneous transluminal coronary an-
gioplasty (Bond 2007b; Kiessling 2002; Moher 2001a (GP led);
Moher 2001b (nurse led); SPHERE); five recruited patients with
angina or previous acute myocardial infarction (Campbell 1998;
Cupples 1994a; Feder 1999; Munoz 2007; SHIP 1999); one re-
cruited patients with angina (Eccles 2002) and one patients with
previous coronary artery bypass graft (Gao 2007). Study popula-
tions ranged from 58%male to 85%male with mean ages ranging
from 62.0 to 68.8 years. Only one study was set outside Europe.
Details regarding population sizes, diagnostic profiles, age, study
location, length and intervention characteristics are presented in
Characteristics of included studies and Table 1.
Five studies were conducted in England, two in Ireland (one in
Northern Ireland and one in both Northern Ireland and the Re-
public of Ireland), one in China, one in Spain, one in Scotland and
one in Sweden. Further details of the studies and interventions are
presented in this section.
Our search strategy identified the protocol of the SPHERE study
and the study was completed in October 2007, prior to the search
date. The Heart Group advised that the study could be included
and the investigators provided the data for the review. The study
report has since been published (SPHERE).
We received additional data and information about studies from
the authors of five studies (Cupples 1994a; Kiessling 2002;Munoz
2007; SHIP 1999; SPHERE). Attempts to contact Chinese trial-
ists for supplementary data failed.
The eligible studies identified involved considerable variation in
both the outcomesmeasured and the elements of the interventions.
We considered the elements of the interventions carefully and
categorised them. Each study could then be considered in terms of
the elements involved in the interventions which were additional
to normal care in order to facilitate consideration of those elements
which are most often associated with improved outcomes.
Elements of interventions additional to normal care which were
identified were as follows:
1. Structured monitoring and assessment of risk factors and
medications
2. Preplanned appointment/s / patient recall
3. Patient education or awareness raising regarding secondary
prevention: risk factors, medications and lifestyle
4. Clinician education or awareness raising regarding
secondary prevention: promotion of clinical guidelines, clinical
management advice, education or training
5. Improved secondary/primary care interface
6. Information technology based decision supports
7. Nurse proactive in care management
8. Pharmacist proactive in care management
Planned monitoring and assessment of risk factors and medica-
tions were central elements in many of the study interventions.
Three studies featured risk factor and medication monitoring by
doctors or nurses or both (Campbell 1998; Gao 2007; SPHERE).
One of the studies focused on the review by community phar-
macists of prescribing to IHD patients, with recommendations
being sent to the patients’ general practitioners (GPs). This study
included patients with angina, previous acute myocardial infarc-
tion and revascularisation and in addition to medication, patients’
compliance, lifestyle and social issues were also assessed, with pa-
tients recalled by the pharmacist as they felt necessary for effective
monitoring (Bond 2007b). Pre-planned appointments for patients
to see clinicians was a feature of many of the interventions: in some
studies these appointments followed discharge following an acute
admission or hospital clinic attendance (Gao 2007; SHIP 1999);
in others the patients were selected randomly from a prevalent
practice population of people with IHD (SPHEREa); in still oth-
ers entire practice populations were invited to participate (Bond
2007b; Campbell 1998; Cupples 1994a; Moher 2001a (GP led);
Moher 2001b (nurse led); Munoz 2007). Several interventions in-
cluded the provision to patients of secondary preventive advice and
education about risk factors, lifestyle and medication (Campbell
1998; Cupples 1994a; Feder 1999;Gao 2007; SPHERE). In other
interventions education or training was aimed at clinicians: in
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some this involved direct training or educational meetings aimed
at raising standards in the provision of secondary preventive care,
while in others the focus was on raising the awareness of secondary
prevention guidelines (Eccles 2002; Feder 1999; Kiessling 2002;
Moher 2001a (GP led); Moher 2001b (nurse led); Munoz 2007;
SHIP 1999; SPHERE). Two study interventions involved efforts
to ensure a smooth transition for patients from hospital-based care
to primary care following discharge (Gao 2007; SHIP 1999) and
one featured a computer-based decision support system aimed at
improving secondary prevention (Eccles 2002). Some interven-
tionswere principally led by or focused upon doctors (Eccles 2002;
Feder 1999; Gao 2007; Kiessling 2002; Moher 2001a (GP led)),
nurses (Campbell 1998; Cupples 1994a; Moher 2001b (nurse
led)), community pharmacists (Bond 2007b) or both nurses and
doctors (SHIP 1999; SPHERE). One study contained three arms,
including one which was doctor-centred and one nurse-centred:
the first arm comprised simply an audit of secondary preventive
care in practices, followed by normal care and is considered as the
control for the purposes of analysis in this review; the second arm
comprised audit, creation of a register of patients with IHD and
routine recall to appointments with the GP; the third comprised
audit, creation of an IHD register and recall to nurse-led IHD
clinics (Moher 2001a (GP led); Moher 2001b (nurse led)). This
was considered as two studies and we split the data from the nor-
mal care arm to avoid double-counting.
As discussed, the delivery of health care is organised in many dif-
ferent ways around the world and “primary care” exists as neither
a term nor a concept in some. Yet we considered it essential that
studies should not be excluded for reasons of semantics or health
system differences. One Chinese study, reported inMandarin, was
considered at length and translated twice. We included it because
although it was led by hospital-based physicians, this was represen-
tative of the manner in which health care was normally available
to the participants and communities involved. Both the normal
care and the intervention arms involved both hospital and com-
munity-based health care (Gao 2007).
Heterogeneity
We identified several potential sources of heterogeneity a priori
and implemented strategies such as careful definition of terms and
sensitivity analysis to alleviate their effects and enable quantita-
tive meta-analysis. However, additional sources of heterogeneity
emerged that further compromised meta-analysis. The outcome
measures set for the review were improved patient and clinician
adherence to internationally accepted recommendations for the
secondary prevention of IHD (De Backer 2003; Wood 1998a).
These recommendations provide target levels for scale risk factor
measurements such as blood pressure, cholesterol and body mass
index (BMI) and categorical indicators of appropriate secondary
preventive care such as prescribing of prophylactic medications
and smoking cessation. Given these well-defined and widely ac-
cepted measurements of successful secondary preventive care, the
wide variation in trial outcome measurements was surprising and
reduced the opportunities for meta analysis.
Few trialsmeasured the same outcomes.More surprising and prob-
lematic, there was frequent deviation from accepted target lev-
els for risk factors. Some deviation resulted from changes in the
accepted levels through time, but some could not be explained.
For example, thresholds used for determination of hypertension
were variously set at 140/90 mmHg (De Backer 2003; Gao 2007;
Wood 1998a), 160/90mmHg (Campbell 1998), 160/100 mmHg
(Moher 2001a (GP led)), and 140/85 mmHg (Bond 2007b). The
way in which outcomes were recorded varied: in some trials the
numbers of those prescribed medications were recorded, in others
those “prescribed, not in need of the drug or contraindicated”.
In some “known smokers” were recorded, in others “known non-
smokers”, leaving an indeterminate subgroup whose status was
unknown. Some trials recorded numbers of patients with BMI
<25 kg/m2, others reportedmean BMI. Some studies devised out-
comes which were intended to indicate whether certain risk fac-
tors were “adequately” or “appropriately” assessed or managed, but
the standards by which adequacy was judged varied (Bond 2007b;
Campbell 1998; Moher 2001a (GP led)).
Despite cooperation of many trial researchers, data that could be
pooled were not available in many cases. They had not been col-
lected. Compounding this problem was the range of follow-up
periods, with six studies following participants for 12 months, two
for 18 months, two for 24 months and one for 36 months. Con-
sequently, given the variation in reported outcomes and follow-up
times, data could be pooled for relatively few outcomes. Methods
of reporting results, the diverse nature of the data collected and
the relatively small numbers of studies that could be pooled meant
that subgroup analysis was not viable.
Given the inevitable heterogeneity in trials of service organisa-
tional interventions, we gave the issue careful consideration at each
analysis. We used random effects models in meta-analyses where
the I2 statistic, visual inspection of the forest plots and consider-
ation of study populations, interventions and settings suggested
high levels of heterogeneity.
Individual and cluster randomisation
Seven of the included studies were randomised at cluster level
(Eccles 2002; Feder 1999; Kiessling 2002;Moher 2001a (GP led);
Moher 2001b (nurse led); Munoz 2007; SHIP 1999; SPHERE)
and the rest used individual randomisation. In order that the data
from cluster and individually randomised trials could be com-
bined, we calculated effective sample sizes for the cluster-ran-
domised trial using the approach described in theCochraneHand-
book for Systematic Review of Interventions. Using themean clus-
ter size for each trial and intracluster correlation coefficients, ef-
fective sample sizes were calculated which accounted for the clus-
ter design effect. Some studies calculated and reported intraclus-
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ter correlation coefficients (Eccles 2002; Feder 1999; SPHERE):
these ranged from0.045 to 0.062 and given the similarity in popu-
lations and settings an approximate middle value intracluster cor-
relation coefficient of 0.05 was used for those that did not.
Strategy for evidence synthesis
Multidimensional heterogeneity in interventions, settings, popu-
lations and baseline care levels were thus compounded by varia-
tions in outcome measurements and length of follow up. In such
circumstances it can be argued that meta-analysis is inappropriate.
Nevertheless meta-analyses were possible for several comparisons
and in many cases showed some consistency in effect across stud-
ies.
The ultimate purpose of the review is to help to inform the de-
velopment of secondary prevention in primary care. In order to
fulfill this purpose as effectively as possible, meta-analyses were
conducted where possible and are reported, supplemented by nar-
rative consideration of what the evidence suggests about the inter-
ventions and their settings, why interventions have the effect they
do (or do not), and of relationships between studies.
Risk of bias in included studies
The risk of bias in included studies was judged in accordance with
the guidance in the Cochrane Handbook for Systematic Review
of Interventions Cochrane Handbook 2008a.
Summary of risk of bias in included studies.
Adequate sequence generation
Details of sequence generation were reported for all but one study,
or were provided when trialists were contacted. Computer pro-
grammes and random number tables were most commonly used,
with coin tossing used by one study. The Chinese trial was clearly
reported as a randomised controlled trial, but no details of the
methods of randomisation could be accessed (Gao 2007).
Allocation concealment
For all but one study, central allocation was reported. No details
for the Chinese trial could be accessed (Gao 2007).
Blinding
Patients were blinded to allocation in three trials (Eccles 2002;
Kiessling 2002 ;Moher 2001a (GP led);Moher 2001b (nurse led))
but could not be blinded in the rest because of the nature of the
interventions. Outcome measurement was blinded in five of the
studies. The authors judged that lack of blinding did not affect
outcomes.
Incomplete outcome data addressed
For all studies, missing data were reported and there was no reason
in any to believe that the proportion of or reasons for missing
outcomes were sufficient to have a clinically relevant impact on
observed effect size.
Selective reporting
All studies appeared free from selective reporting although proto-
cols were not available for all.
Other bias
One study reported that despite clinician blinding, there may have
been contamination of the control group by the presence of the
intervention in the practices (Campbell 1998). However, the trial-
ists and review authors judge that this effect, if any, was unlikely to
have a clinically relevant impact on observed effect size. All other
studies appear free from other sources of bias.
Publishing bias
Funnel plots were generated and none was suggestive of publica-
tion bias. However, in general the analyses contained insufficient
studies for funnel plots to be particularly efective in highlighting
such bias.
Effects of interventions
Clinical risk factors
Blood pressure
Blood pressure within recommended level
Three studies comparing service organisation interventions with
normal care reported data for 3126 participants on blood pres-
sure within the study target level at 12 months (Bond 2007b;
Campbell 1998; Gao 2007). When data were pooled the asso-
ciation between service interventions and blood pressure within
recommended levels bordered upon statistical significance, with a
combined OR of 1.77 (95% CI 1.00 to 3.16) (Figure 1). How-
ever, there was a high degree of heterogeneity in this analysis in
terms of study populations, interventions and settings as well as
in effect size: one study was a UK pharmacist led intervention
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amongst people with all forms of IHD included in this review (OR
1.05 (95% CI 0.84 to 1.30)) (Bond 2007b), one a UK nurse led
intervention amongst people with angina or previous acute my-
ocardial infarction (OR 1.78 (95% CI 1.35 to 2.34) (Campbell
1998) and the third a physician led intervention amongst peo-
ple with previous coronary artery bypass graft in China (OR 3.62
(95% CI 1.97 to 6.66)) (Gao 2007). The Chinese trial, which
had the most significant effect, included only post coronary artery
bypass graft patients, who may have been more easily motivated
by structured and sustained secondary preventive care than those
who had not undergone such major surgery and were included in
other trials (Gao 2007). In addition, methods of randomisation
and allocation concealment were uncertain in this trial. In both
analyses there was no statistically significant effect when this trial
was removed. Each of the three trials in the 12 month analysis had
in common routine planned recall of patients for appointments
and structured monitoring of risk factors and medications. Two
of the three also included secondary prevention patient lifestyle
education (Campbell 1998; Gao 2007), two included secondary
prevention training or awareness-raising initiatives for clinicians
(Bond 2007b; Campbell 1998) and one included improved sec-
ondary/primary care interface (Gao 2007). The borderline signif-
icant association of interventions and blood pressure within tar-
get levels at 12 months was lost when 18 month data from the
SPHERE trial were added (Figure 2).
Figure 1. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.1 Blood
pressure within study protocol target level at 12 months.
Figure 2. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.2 Blood
pressure within study protocol target level at end of study (per protocol).
Mean blood pressure
Data could be pooled for three intervention arms in two trials
(Moher 2001a (GP led); Moher 2001b (nurse led); SPHERE)
relating to systolic and diastolic blood pressures in 646 partici-
pants at 18 months (Figure 3; Figure 4). No significant effect of
the interventions was detected. All these intervention arms in-
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cluded planned appointments and patient recall and clinician ed-
ucation or awareness relating to secondary prevention. Data could
be pooled for five intervention arms in four trials (Cupples 1994a;
Moher 2001a (GP led); Moher 2001b (nurse led); SHIP 1999;
SPHERE) relating to systolic and diastolic blood pressures at end
of study per protocol (Figure 5; Figure 6). Again, no significant
intervention effect was detected. Of the interventions included
in trials which reported blood pressure outcome data, two were
principally doctor-led, one pharmacist-led, two nurse-led and one
doctor and nurse-led. The profession of the lead clinician does not
appear to relate to results.
Figure 3. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.3 Mean systolic
blood pressure at 18 months.
Figure 4. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.4 Mean
diastolic blood pressure at 18 months.
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Figure 5. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.5 Mean systolic
blood pressure at end of study (per protocol).
Figure 6. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.6 Mean
diastolic blood pressure at end of study (per protocol).
Total cholesterol
Total cholesterol within recommended level
Two studies comparing interventions with normal care reported
data for total blood cholesterol level with recommended limits
in 1685 participants at 12 months (Campbell 1998; Gao 2007;
Figure 7) and three at end of study period per protocol in 2173 par-
ticipants (two at 12 months, one at 18 months) (Campbell 1998;
Gao 2007; SPHERE; Figure 8). There was a significant associa-
tion between the interventions and total cholesterol levels within
recommended levels at 12 months, with an OR of 1.90 (1.04 to
3.48), with the Campbell study being associated with the great-
est improvement, with an OR of 2.48 (1.93 to 3.18). There was
no significant intervention effect when the three were combined.
All three interventions included structured monitoring of risk fac-
tors and medication, planned regular recall of patients and pa-
tient lifestyle education. Two of the three also included secondary
prevention training or awareness-raising initiatives for clinicians
(Campbell 1998; SPHERE). There was a high level of hetero-
geneity in the included studies. One included only post coronary
artery bypass graft patients, one angina and post acute myocardial
infarction patients, and one all categories of IHD patients. In ad-
dition, the trial which contributed most to the significant pooled
result is considerably older than the other two, so that baseline
levels of cholesterol compliance in primary care populations may
have been lower and therefore easier to improve upon (Campbell
1998).
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Figure 7. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.7 Total blood
cholesterol within study protocol target level (5.2 mmol/l) at 12 months.
Figure 8. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.8 Total blood
cholesterol within study protocol target level at end of study.
Mean total cholesterol
Four studies reported mean total cholesterol levels at end of study
period (Cupples 1994a; Kiessling 2002; SHIP 1999; SPHERE).
No significant effect was detected (Figure 9). Whilst there was
homogeneity in effect size, there was considerable heterogeneity
in the nature of the interventions: one comprised planned patient
recall to appointments and patient lifestyle education (Cupples
1994a), one planned recall, clinician education and awareness-
raising and improved secondary/primary care interface (SHIP
1999), one clinician education alone (Kiessling 2002), and one
stuctured risk factor and medication monitoring, planned patient
recall and education for both clinicians and patients (SPHERE).
No heterogeneity was observed in these analyses.
13Service organisation for the secondary prevention of ischaemic heart disease in primary care (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.9 Total blood
cholesterol at end of study (per protocol).
Prescription of prophylactic medications
Prescribing: lipid lowering drugs
Three intervention arms in two trials reported data for levels of
appropriate prescribing of lipid lowering drugs at 18 months (
Moher 2001a (GP led); Moher 2001b (nurse led); SPHERE).
Pooled data did not show a significant effect of the interventions
on prescribing (Figure 10). Six intervention arms in five trials
reported data for prescribing of lipid lowering drugs at end of
study as per protocol (Eccles 2002; Feder 1999;Moher 2001a (GP
led); Moher 2001b (nurse led); Munoz 2007; SPHERE; Figure
11). No significant intervention effect was detected.
Figure 10. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.10 Prescribed
lipid-lowering medication at 18 months.
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Figure 11. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.11 Prescribed
lipid-lowering medication at end of study.
Prescribing: beta blockers
Three trials reported data for levels of appropriate prescribing of
beta blockers at end of study period per protocol (Eccles 2002;
Munoz 2007; SPHERE). Neither pooled data nor any of the trials
individually detected a significant effect of the interventions on
prescribing (Figure 12).
Figure 12. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.12 Prescribed
beta blockers at end of study.
Prescribing: ACE inhibitors
Two trials reported data for levels of appropriate prescribing of
ACE inhibitors at end of study period per protocol (Munoz 2007;
SPHERE). Pooled data did not show a significant effect of the
interventions on prescribing. Both study interventions included
very similar elements (Figure 13).
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Figure 13. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.13 Prescribed
ACE inhibitors at end of study.
Prescribing: anti-platelets
Three intervention arms in two trials reported data for levels of ap-
propriate prescribing of anti-platelets at 18 months (Moher 2001a
(GP led); Moher 2001b (nurse led); SPHERE). No significant
association was detected between the interventions and improved
prescribing levels (Figure 14). Six intervention arms in five trials
reported data for levels of appropriate prescribing of anti-platelets
at end of study period per protocol (Bond 2007b; Campbell 1998;
Moher 2001a (GP led); Moher 2001b (nurse led); Munoz 2007;
SPHERE). No significant association was detected between the
interventions and improved prescribing levels (Figure 15). There
was some heterogeneity which seemed to suggest a temporal ef-
fect: when older trials, conducted in the 1990s, were considered
together there was a significant intervention effect on prescribing
(Campbell 1998; Moher 2001a (GP led); Moher 2001b (nurse
led)), whilst those conducted since 2000 remained had little effect.
Figure 14. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.14 Prescribed
anti-platelet medication at 18 months.
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Figure 15. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.15 Prescribed
inti-platelet medication at end of study.
Lifestyle risk factors
Exercise
Three trials reported data for exercising at or above recommended
levels at end of study period per protocol (Bond 2007b; Campbell
1998; SPHERE). No statistically significant intervention effect
was detected (Figure 16).
Figure 16. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.16 Exercising
at or above study target level at end of study.
Diet
No data could be pooled relating to diet. Two studies reported
data on the effect of a service organisation intervention on diet.
Whilst one reported no significant effect on fruit and vegetable
consumption (SPHERE), one showed a significant positive asso-
ciation between intervention and maintaining a low fat diet, OR
1.47 (95% CI 1.10 to 1.96) (Campbell 1998).
Smoking cessation
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Three trials reported data for levels of smoking cessation (or non-
smoker status) at end of study period per protocol (Bond 2007b;
Campbell 1998; SPHERE). Pooled data detected no significant
effect associated with the interventions (Figure 17).
Figure 17. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.17 Smoking
cessation at end of study.
Obesity
Three trials reported data for levels of Body Mass Index at end of
study periodper protocol (Cupples 1994a; SHIP1999; SPHERE).
Neither pooled data nor any of the trials individually detected a
significant effect of the interventions (Figure 18).
Figure 18. Forest plot of comparison: 1 Service organisation versus normal care, outcome: 1.18 Body mass
index at end of study.
Elements of interventions
Structured monitoring and assessment of risk factors and
medications
Structured monitoring and assessment of risk factors and med-
ications were elements in interventions associated with positive
effects on outcomes. They were included in all the interventions
whose pooled data indicated an association with improved levels
of blood pressure within recommended levels that bordered on sig-
nificance (Bond 2007b; Campbell 1998; Gao 2007), and the in-
terventions whose pooled results were significantly associated with
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improved levels of total blood cholesterol within recommended
levels (Campbell 1998; Gao 2007).
Preplanned appointment/s / patient recall
All the interventions whose pooled data indicated an association
with improved blood pressure outcomes that bordered on signif-
icance included preplanned patient appointments or regular pa-
tient recall to their care providers (Bond 2007b; Campbell 1998;
Gao 2007). The interventions whose pooled data are associated
with improved levels of total cholesterol within recommended
levels included preplanned appointments or regular patient recall
(Campbell 1998; Gao 2007), as did the older intervention trials
associated with improved levels of appropriate prescribing of an-
tiplatelets (Campbell 1998;Moher 2001a (GP led);Moher 2001b
(nurse led)).
Patient education or awareness raising regarding secondary
prevention: risk factors, medications and lifestyle
The interventionswhose pooled data indicated an association with
improved levels of blood pressure within recommended levels that
bordered on significance included secondary prevention patient
lifestyle education (Bond 2007b; Campbell 1998;Gao 2007). The
interventions whose pooled data are associated with improved lev-
els of total cholesterol within recommended levels included pa-
tient lifestyle education (Campbell 1998; Gao 2007).
Clinician education or awareness raising regarding
secondary prevention: promotion of clinical guidelines,
clinical management advice, education or training
Two of the three interventions whose pooled data indicated an as-
sociationwith improvedbloodpressure outcomes that bordered on
significance included secondary prevention training or awareness-
raising initiatives for clinicians (Bond 2007b; Campbell 1998).
One of the interventions whose pooled data are associated with
improved levels of total cholesterol within recommended levels
also included secondary prevention training or awareness-raising
initiatives for clinicians (Campbell 1998).
Improved secondary/primary care interface
Improved secondary/primary care interface was included in one
trial intervention that contributed to improvements in blood pres-
sure outcomes and cholesterol outcomes (Gao 2007).
Information technology based clinical supports
An information technology based clinical support system was in-
cluded in one trial intervention (Eccles 2002). The trial did not de-
tect any effect on secondary preventive care. However, the trialists
reported that the system was not widely used in the intervention
practices because it was found not to integrate well with clinical
encounters. The large population involved meant that the lack of
effect in this study affected the meta-analysis of other interven-
tions. When removed from the analysis, the pooled data from the
five remaining interventions (which were not technology based)
indicated a significant association between interventions and im-
proved appropriate prescribing of lipid lowering drugs.
Nurse proactive in care management
Nurses were proactive clinical participants in six of the interven-
tions included, either as principal intervention clinician or co-or-
dinator or in partnership with doctors Campbell 1998; Cupples
1994a; SHIP 1999; Moher 2001b (nurse led); Moher 2001a (GP
led); SPHERE. There is no evidence to suggest that nurse-centred
interventions are associated with better outcomes than any other.
Pharmacist proactive in care management
Community pharmacists were the principal intervention primary
care professional in one of the included studies, in which they
worked alongside doctors but delivered much of the intervention
to patients (Bond 2007b). There is no evidence to suggest that
pharmacist-led interventions are asssociated with better outcomes
than any other.
D I S C U S S I O N
There was inevitably considerable heterogeneity in studies in-
cluded in this review of complex interventions in complex health-
care settings. However, identification of sources of heterogneity
a priori and development of strategies to address these, identifi-
cation of hetergeneity in meta-analyses and the use of random-
effects models meant that some pooling was possible. However,
although included studies were generally of good quality, results
of meta-analyses undertaken in a context where heterogeneity and
complexity are prevalent must be interpreted with caution. The
generalisability of the results of the review is uncertain as the pop-
ulations included in the trials were predominantly men with mean
age ranging from 62.0 to 68.8 years in European countries.
There was some weak evidence that beneficial effects in terms
of the number of patients whose cholesterol and blood pressure
levels were within target levels are associated with primary care
interventions that include preplanned recall of patients, system-
atic monitoring of risk factors and medication, patient education
or awareness-raising in relation to secondary prevention and to a
lesser degree clinician education or awareness-raising in relation to
secondary prevention recommendations. Only a meta-analysis of
two very different trials measuring cholesterol levels within target
levels at 12 months showed true statistical significance, whilst a
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meta-analysis of three trials measuring blood pressure within tar-
get levels bordered on significance. However, there was consider-
able heterogeneity in the trials included in both these analyses.
No significant intervention effects were detected relating to mean
blood pressure or cholesterol levels. Little evidence was found that
could shed light on whether such interventions also offer benefit
in relation to other lifestyle-centred risk factor outcomes such as
diet, obesity and smoking. One trial showed a significant asso-
ciation between such an intervention and maintaining a low fat
diet (Campbell 1998). There was little evidence to suggest that
service organisational interventions are associated with improved
outcomes in the prescribing of prophylactic medications.
A “ceiling effect”, whereby it becomes more difficult to show ben-
efits once a certain baseline level of treatment has been reached,
has been discussed in the context of diabetes care (Davies 2008)
and there is some evidence from the included studies that suggest
this may be the case in the secondary prevention of IHD, although
it must be acknowledged that this is a post hoc analysis. For ex-
ample, when prescribing of antiplatelets was considered, senstivity
analysis showed that when older trials, conducted in the 1990s,
were considered together, therewas a significant intervention effect
on prescribing (Campbell 1998; Moher 2001a (GP led); Moher
2001b (nurse led)), whilst those conducted since 2000 had little
effect. The lack of significant effect of these interventions on pre-
scribing behaviours may not relate to their inherent ineffective-
ness, but to more aggressive and effective targeting of prophylaxis
in Europe in the years since the Recommendations of the Second
Joint Task Force of European and other Societies onCoronary Pre-
vention (Wood 1998a). A similar temporal effect may have con-
tributed to the significant intervention effect on cholesterol levels
within study targets: the trial which contributed most to the effect
dated from the early 1990s, when baseline cholesterol levels were
higher and more easily improved (Campbell 1998). The dimin-
ishing returns associated with a “ceiling effect” may be seen also in
the blood pressure analysis, in which the Chinese trial has a much
greater effect than any other. This may relate to a difference in the
trial population, which included only post-coronary artery bypass
graft patients who may be more easily motivated than others by
structures and sustained secondary preventive care, but it may also
reflect the effect of the introduction in the intervention group of
a structured care model in a healthcare system where normal care
for the control group included no regular recall or structured risk-
factor monitoring (Gao 2007).
It remains difficult to saywhich elements of service organisation in-
terventions have most effect on outcomes. There were not enough
trials included in meta-analyses for sensitivity analysis to be able to
detect which elements of interventions were associated with most
benefit. It is true that, in this review, significant beneficial effect
was associated with interventions which included patient and clin-
ician education or awareness-raising in relation to secondary pre-
vention recommendations, preplanned recall of patients and sys-
tematic monitoring of risk factors and medication. However, this
is not to say that other elements may not be as important, simply
that evidence for their effectiveness has not been detected. The
data included in this review relate to interventions whose principal
service providers have been doctors, nurses and community phar-
macists working both closely with other primary care profession-
als and relatively independently. However, there were insufficient
studies or data to suggest that the effectiveness of interventions is
affected by the type of primary care professional that leads.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is limited evidence that interventions centred on alterations
in the way secondary prevention is provided in the primary care
context can be effective in improving patient compliance with
recommendations on blood cholesterol and blood pressure levels.
The interventions associated with these improved outcomes in-
cluded patient secondary prevention education or awareness-rais-
ing, preplanned recall of patients and systematic monitoring of
risk factors and medication.
Once secondary preventive care reaches certain levels it may be-
come more difficult for interventions to achieve further benefit.
Service organisation interventions aimed at improved secondary
preventive care for people with IHD should be implemented in
regions and populations where current secondary preventive care
does not follow a structured and sustained model.
Implications for research
Trials of complex interventions in primary care aimed at improved
secondary prevention of IHD should focus on patient lifestyle-
related outcomes. However, there needs to be greater co-operation
between researchers in different countries to ensure standardisa-
tion of the outcomes measured in such studies if systematic re-
viewing is to be effective in evaluating and describing the evidence
base. Given that there may be a “ceiling effect”, whereby it is hard
to detect benefit of secondary preventive measures in the whole
IHD population once a certain baseline level of prescribing has
been reached, it may be useful to conduct research in populations
at higher risk of subsequent IHD events. Previous research has
highlighted the fact that, while clinicians are supportive of sec-
ondary prevention guidelines, considerable barriers exist that af-
fect implementation. Other research methods such as qualitative
studies may be of use in identifying a new testable hypothesis of
how this gap could be closed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bond 2007b
Methods Community pharmacist consultation and case management of medication
Randomisation by individual
Participants 1493 men and women with IHD (AMI, Angina, PTCA, CABG), 62 pharmacists, 164
GPs in England. 68.5% males; mean age (SD) 68.7 (9.2) in intervention group, 68.8
(9.1) in control
Interventions Initial patient-pharmacist consultation to review appropriateness of therapy, compliance,
lifestyle, social and support issues. Further consultations as judged by pharmacists. Re-
ports sent to GPs
Control patients received normal care.
Outcomes At 12 months: Prescribed aspirin (or antiplatelet, or contraindicated or refused) % (n/
N); statins % (n/N); blood pressure < 140/85 mm/Hg; non-smoker % (n/N); physical
activity as per NSF % (n/N); BMI < 25 kg/m2 % (n/N).
Notes Intention-to-treat analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation conducted indepen-
dently of the research team
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants could not be blinded to alloca-
tion due the the nature of the intervention.
Researchers and outcome assessors blind to
allocation. Review authors judge that the
outcomes are not likely to be affected by
lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported in the
flow chart of the trial. Reasons for miss-
ing outcome data unlikely to be related
to outcomes. Imbalance between interven-
tion and control group likely to relate to
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Bond 2007b (Continued)
increased participant burden in interven-
tion groups compared with the normal care
control group. The proportion of missing
outcomes compared with observed events
is not sufficient to have a clinically relevant
impact on observed effect size
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Campbell 1998
Methods Nurse-run clinics in general practice for secondary prevention of IHD
Randomisation by individual
Participants 1173 men and women with IHD in 19 general practices in NE Scotland. 58.4% males;
mean age (SD) 66.1 (8.2) in intervention group, 66.1 (8.2) in control
Interventions Nurse-run IHD secondary prevention clinics in general practices for 12months assessing
and monitoring risk factor managment and making medication referrals to GPs. The
control group received normal care from their GP
Outcomes “Appropriate secondary prevention” (according to guidelines) at baseline and 12months:
aspirin taken or contraindicated n/N (%); blood pressure < 160/90 or receiving attention
(treated, checked w/in 3 mo or referred) n/N (%); total cholesterol < 5.2 mmol/l or
receiving attention (treated, checked w/in 3 mo or referred) n/N (%); moderate physical
activity, not smoking and following a low fat diet n/N (%)
Notes Intention-to-treat analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised by random num-
ber table.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants could not be blinded to alloca-
tion due the the nature of the intervention.
Review authors judge that the outcomes are
not likely to be affected by lack of blinding
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Campbell 1998 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data fully reported and balanced in
numbers and reasons across groups
Selective reporting (reporting bias) Low risk Study protocol available and all pre-speci-
fied outcomes are reported in the pre-spec-
ified way
Other bias Low risk Trialists report that despite clinician blind-
ing, there may have been contamination of
the control group by the presence of the
intervention in the practices. However, the
trialists and review authors judge that this
effect, if any, was unlikely to have a clin-
icially relevant impact on observed effect
size
Cupples 1994a
Methods General practice-delivered health education for people with angina. Randomisation by
individual
Participants 688 men and women < 75 years of age with angina for > 6months in 18 general practices
in Belfast area. 59% males; mean age (SD) 62.7 (7.1) in intervention group, 63.6 (6.8)
in control
Interventions Individually delivered IHD-related health education at four-monthly reviews over two
years
Outcomes Mean diastolic and systolic blood pressure, mean total serum cholesterol, mean BMI at
baseline and 24 months
Notes Authors contacted for additional data.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants randomised by random num-
ber table.
Allocation concealment (selection bias) Low risk Allocation by opaque, sealed envelope con-
taining allocation, generated from random
number tables
Blinding (performance bias and detection
bias)
All outcomes
Low risk Participants could not be blinded to alloca-
tion due to the nature of the intervention.
Outcome assessors blind to allocation. Re-
view authors judge that the outcomes are
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Cupples 1994a (Continued)
not likely to be affected by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data fully reported with no differ-
ences found between intervention and con-
trol groups
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Eccles 2002
Methods Cluster randomised controlled before and after two by two incomplete block design trial
Randomisation by practice
Participants Total practice angina populations from 60 general practices in NE England (2240 men
and women with angina)
Interventions Introduction of computer-based decision support system aimed at implementation of
clinical guidelines for angina. The control group received normal care from their GP
Outcomes Recording of blood pressure, smoking status and cholesterol at 12 months prior to
intervention, baseline and 12 months f/up n/N (%). Prescription of statins and beta-
blockers at baseline and 12 months n/N (%)
Notes Intention to treat analysis. The study report acknowledges that the computer-based
decision support systems introduced in the intervention practices were found to have
some difficulties in use and that this may have accounted for the lack of intervention
effect
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patient participants blinded to practice al-
location. Practice staff could not be blinded
to allocation due to the nature of the in-
tervention but the outcomes and outcome
measurements are unlikely to have been in-
30Service organisation for the secondary prevention of ischaemic heart disease in primary care (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Eccles 2002 (Continued)
fluenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcomes reported fully. The pro-
portion of missing outcomes compared
with observed events is not sufficient to
have a clinically relevant impact on ob-
served effect size
Selective reporting (reporting bias) Low risk The protocol is available and it is clear
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Feder 1999
Methods Controlled trial of postal prompts. Randomisation by practice
Participants 328men andwomendischarged fromHomertonHospital, London, following admission
for AMI or angina. Patients recruited on discharge. On consent, their practice was
randomised. Subsequent consenting patients from the same practice joined the control or
intervention groups by practice. 52 general practices in East London, UK, were involved.
59% males; mean age 66.4 in intervention group, 64.8 in controls
Interventions Intervention at 2 weeks and 3 months after discharge: leaflets posted to patients contain-
ing recommendations for lowering IHD risk, including lifestyle changes, drug treatments
and making an appointment to attend GP or practice nurse; letters to GPs referring to
appropriate secondary prevention and guidelines
Control: normal care.
Outcomes Cholesterol recording and cholesterol lowering drugs (statins) % (n/N) at baseline and
12 months
Notes Only data for cholesterol recording and lipid lowering drug prescribing to patients en-
rolled early were available at 12 months. Other outcomes were recorded at 6 months
Available case analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation.
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Feder 1999 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Patients and practice staff could not be
blinded to allocation due to the nature of
the intervention but the outcomes and out-
come measurements are unlikely to have
been influenced by lack of blinding. Out-
come assessors were blind to allocation but
may have seen evidence of the intervention
in patient records while data collecting so
that it is possible that they would be un-
consciously biased towards noticing posi-
tive data in the records of interventionprac-
tices
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors believe reasons for missing
outcome data are unlikely to be related to
outcomes
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Gao 2007
Methods Controlled trial of health management post-CABG. Randomisation by patient
Participants 342 post-CABG patients in Tongji, China. 68% males; mean age 62 (±11)
Interventions Intervention group: cardiac rehabilitation followed by health education and planned
continued risk factor monitoring and management by doctors and community medical
unit; clinicians proactive in arranging patient recall
Control group: normal cardiac rehabilitation followed by normal community care; pa-
tients responsible for arranging continuing care
Outcomes Blood pressure >140/90 mm/Hg n/N (%), total blood serum cholesterol > 5.2 mmol/l
n/N (%) at baseline and 12 months
These outcomes are as per local guidelines at the time of the trial and as specified in the
protocol
Notes Available case analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
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Gao 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk The study is described by trialists as ran-
domised, but no details are given about the
precise method used
Allocation concealment (selection bias) Unclear risk No details are given about the precise
method used.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and practice staff could not be
blinded to allocation due to the nature of
the intervention but the outcomes and out-
come measurements are unlikely to have
been influencedby lack of blinding. It is un-
clear whether outcome assessors were blind
to allocation but it is unlikely that the out-
comes and outcome measurements are un-
likely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for missing data reported and un-
likely to be related to outcome
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Kiessling 2002
Methods Prospective controlled trial of intervention aimed at improved secondary preventive care
Randomisation by practice.
Participants 88 men and women with IHD from 14 primary care practices in Stockholm County,
Sweden. All practice patients who had attended secondary care with AMI or angina in
the preceding year invited. 85% males; mean age (SD) 62.6 (6.1) in intervention group,
62.3 (7.4) in controls
Interventions Intervention: direct distribution of guidelines on cholesterol management; 3 or 4 case
method learning seminars held at each primary care centre to encourage discussion and
learning relating to the care of IHD patients and secondary prevention of IHD
Control: direct distribution of guidelines on cholesterol management; normal care
Outcomes Mean total and LDL cholesterol at baseline and 24 months - mmol/l (95% CI)
Notes Intention-to-treat analysis.
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Kiessling 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Coin tossing
Allocation concealment (selection bias) Low risk Centrally allocated.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Practice staff could not be blinded to allo-
cation due to the nature of the interven-
tion. Outcome assessors and patients were
blinded as to which group they were allo-
cated to
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors judge that reasons for missing
outcome data are unlikely to be related to
outcomes
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Moher 2001a (GP led)
Methods Pragmatic, unblinded, cluster randomised controlled trial
Randomised by practice, stratified in order to achieve balance at baseline between inter-
vention groups in terms of the main outcome measure
Participants 1906 men and women, total practice populations aged 55-75 with IHD in 21 general
practices in England. 67% males; mean age (SD) 66.4 (5.6) in intervention group, 66.
1 (5.4) in controls
Interventions Control: Audit of prevalence of IHD and risk factors in charts and feedback to each
practice. Then normal care (control group)
Intervention: Audit of prevalence of IHD and risk factors in charts and feedback to
each practice. Facilitation of creation of an IHD register and system for regular recall of
patients for review by GP
Outcomes “Adequate” IHD risk factor assessment: dichotomous measurement of “adequate assess-
ment” and, if outside guidelines, ongoing monitoring of blood pressure, cholesterol and
smoking status - mean (practice range); treatment with antiplatelets, lipid lowering and
hypotensive drugs - mean (practice range) at baseline and 18 months
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Moher 2001a (GP led) (Continued)
Notes This trial contained three arms. One was an “audit only” group in which researchers
collected data about IHD prevalence and risk factors from charts. These results were
then fed back to the practices. Similar audits were conducted in the intervention groups,
but audit was not considered in this review as an element of the interventions, since the
audit was common to control and intervention groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were blinded to the study. Practice
staff could not be blinded to allocation due
to the nature of the intervention but the
outcomes and outcome measurements are
unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors judge reasons for missing out-
come data are unlikely to be related to out-
comes
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
Moher 2001b (nurse led)
Methods Pragmatic, unblinded, cluster randomised controlled trial
Randomised by practice, stratified in order to achieve balance at baseline between inter-
vention groups in terms of the main outcome measure
Participants 1906 men and women, total practice populations aged 55-75 with IHD in 21 general
practices in England. 69% males; mean age (SD) 65.8 (5.8) in intervention group, 66.
1 (5.4) in controls
Interventions Control: Audit of prevalence of IHD and risk factors in charts and feedback to each
practice. Then normal care (control group)
Intervention: Audit of prevalence of IHD and risk factors in charts and feedback to
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Moher 2001b (nurse led) (Continued)
each practice. Facilitation of creation of an IHD register and system for regular recall of
patients for review at nurse led IHD clinics
Outcomes “Adequate” IHD risk factor assessment: dichotomous measurement of “adequate assess-
ment” and, if outside guidelines, ongoing monitoring of blood pressure, cholesterol and
smoking status - mean (practice range); treatment with antiplatelets, lipid lowering and
hypotensive drugs - mean (practice range) at baseline and 18 months
Notes This trial contained three arms. One was an “audit only” group in which researchers
collected data about IHD prevalence and risk factors from charts. These results were
then fed back to the practices. Similar audits were conducted in the intervention groups,
but audit was not considered in this review as an element of the interventions, since the
audit was common to control and intervention groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients were blinded to the study. Practice
staff could not be blinded to allocation due
to the nature of the intervention but the
outcomes and outcome measurements are
unlikely to have been influenced by lack of
blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors judge reasons for missing out-
come data are unlikely to be related to out-
comes
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
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Munoz 2007
Methods Multi-centre randomised controlled trial
Randomisation by primary care practice.
Participants 23 practices in Catalonia, Spain; 1022 men and women aged 30-79 with previous di-
agnosis of AMI or angina; all patients within these criteria were invited to participate.
75% males; mean age (SD) 64.2 (9.8) in intervention group, 63.6 (10.3) in controls
Interventions Intervention: distribution to practices of appropriate clinical guidelines; quarterly re-
minders about prescribing,monitoring and provision of lifestyle advice for IHDpatients;
patients received quarterly reminders to arrange appointments with their GP
Control: normal care
Outcomes %(n/N) antiplatelet drugs, Beta-blockers, ACE inhibitors and statins at baseline and 36
months
Also IHD events (mortality, hospital admission and interventions) and risk factor control
expressed as HR according to baseline factors and events
Notes Intention-to-treat analysis.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and practice staff could not be
blinded to allocation due to the nature of
the intervention but the outcomes and out-
come measurements are unlikely to have
been influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors judge reasons for missing out-
come data are unlikely to be related to out-
comes
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
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SHIP 1999
Methods Randomised controlled trial of improved secondary/primary care interface and secondary
preventive care
Randomised by practice
Participants 67 general practices in S England; 597 men and women recruited from all patients dis-
charged from hospital following admission for AMI or recent onset angina; no signifi-
cant differences between control and intervention patients. 71% male; mean age (SD)
63 (10) in intervention group, 64 (10) in controls
Interventions Intervention: trial nurses aimed to improve coordination of care of patients during
transfer from secondary care to primary care following hospitalisation, including prior
arrangement of appointment with GP and provision of information about appropriate
clinical management to the GPs; practice nurses were offered training and ongoing
support in providing structured secondary preventive care
Control: normal care.
Outcomes Mean total cholesterol (mmol/l), mean diastolic and systolic blood pressure (mm/Hg),
mean BMI (kg/m2) and medication.
Notes Hospital-based intervention staff, but working closely with primary care. Primary care
staff provided structured secondary preventive follow up, supported by intervention staff
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and practice staff could not be
blinded to allocation due to the nature of
the intervention but the outcomes and out-
come measurements are unlikely to have
been influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors judge that reasons for missing
outcome data are unlikely to be related to
outcomes
Selective reporting (reporting bias) Unclear risk Althoughnoprotocol is available, it appears
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
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SPHERE
Methods Cluster randomised controlled trial of practice and personal care plans
Randomisation by practice. Practices randomly selected until sufficient consented
Participants 48 general practices in Northern Ireland and the Republic of Ireland
960 men and women with established IHD, randomly selected for initiation to partic-
ipate from registers of total practice IHD populations. 70% male; mean age (SD) 68.5
(9.3) in intervention group, 66.5 (9.9) in controls
Interventions Training for GPs and practice nurses in secondary prevention methods and guidelines.
Patients invited to regularly scheduled consultations aimed at appropriate risk factor
monitoring, medication adjustment and advice. The control group received normal care
from their GP
Outcomes At at baseline and f/up of 18 months: blood pressure mean (SD); blood pressure >140
and >90 mm/Hg; mean (SD) total cholesterol; total cholesterol >5.0mmol/l; mean (SD)
BMI; %(n) self reported smoker
(Also hospital admissions and SF12 health status)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Practices randomised using a computer
programme.
Allocation concealment (selection bias) Low risk Central allocation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Patients and practice staff could not be
blinded to allocation due to the nature of
the intervention but the outcomes and out-
come measurements are unlikely to have
been influenced by lack of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing data are clearly reported. The re-
view authors judge reasons for missing out-
come data are unlikely to be related to out-
comes
Selective reporting (reporting bias) Low risk The protocol is available and it is clear
from the published reports that pre-speci-
fied outcomes measures are reported in the
pre-specified way
Other bias Low risk The study appears to be free of other
sources of bias.
AMI - acute myocardial infarction
39Service organisation for the secondary prevention of ischaemic heart disease in primary care (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CABG - coronary artery bypass graft
PTCA - percutaneous transluminal coronary angioplasty
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ades 2000 Trial was not randomised.
Allen 2002a Intervention staff were primarily hospital-based and interventionwas additional to normal primary care services
Baudet 2006 No randomisation.
Bolman 2002 Hospital-based. Randomisation incomplete.
Bond 2007a In both the published paper and the full report sought from the trialists, outcome data were not reported in a
suitable manner or in sufficient detail for inclusion in the analysis
Brubaker 2000 The staff delivering the intervention operated separately from normal primary care and the intervention was
additional to normal primary care services
Caliani 2004 Trial was not randomised.
Carlsson 1997 Hospital-based intervention.
Carroll 2007 Intervention additional to normal primary care services. No primary care organisational element. Outcomes
not those included in review
Chen 2005 Hospital-based intervention. Outcomes not those included in review
Claesson 2006 Hospital-based intervention additional to normal services.
Clark 1992 Outcomes not those included in review.
Clark 1997 Outcomes not those included in review.
Clark 2000 Outcomes not those included in review.
Coull 2004 Intervention clearly additional to normal primary care services. Outcomes not those included in review
de Lusignan 2004 Outcomes not those included in review.
DeBusk 1994 Intervention clearly additional to normal primary care services
Edworthy 2007 Intervention staff were primarily hospital-based and interventionwas additional to normal primary care services
Fihn 2004 Outcomes not those included in review.
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(Continued)
Frasure-Smith 1997 Outcomes not those included in review.
Goff 2003 The design of the study meant that although the study as a whole lasted several years, the length of follow up of
the same patient groups lasted less than 12 months. The intervention (provision of guideline summaries and
practice performance feedback)was delivered in the summers of 1999, 2000 and2001. Prescribingwas recorded
in subsequent Jan-Mar data collections in 2000, 2001 and 2002. For each of the data collections, practice-
based populations of IHD patients were identified as anyone with recorded IHD attendance or treatment in
the three year periods preceding. Although many patients may have been common to each of the practice-
based populations in each year, details are not reported
Grover 2007 Trial participants not within review inclusion criteria.
Heller 1995 Follow up/study length less than 12 months.
Jiang 2007 Follow up/study length less than 12 months. Substantial proportion of the intervention conducted in hospital
setting
Jolly 2007 The staff delivering the intervention operated separately from normal primary care and the intervention was
additional to normal primary care services
Karoff 2000 Outcomes not those included in review.
Karoff 2000a Intervention hospital based.
Khunti 2007 Intervention peripatetic nurses and extra diagnostic facilities additional to normal primary care services
Koren 2004 Essentially a pharmaceutical trial.
Lapointe 2006 Hospital based study. No primary care organisational intervention
Lear 2002 The staff delivering the intervention operated separately from normal primary care and the intervention was
additional to normal primary care services. No primary care organisational element
Lester 2006 Trial participants not all within review inclusion criteria.
Lichtman 2004 The staff delivering the intervention operated separately from normal primary care and the intervention was
additional to normal primary care services. No primary care organisational element
Masley 2001 Intervention was additional to normal primary care services. No primary care organisational element
McBride 2000 Trial participants not all within review inclusion criteria.
Mittag 2006 Intervention was additional to normal primary care services and delivered by hospital-based staff. No primary
care organisational element
Nordmann 2001 Hospital-based intervention.
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(Continued)
Ornstein 2004 Not purely a secondary prevention study.
Palomaki 2002 Not a randomised trial. Outcomes not those included in review
Pedersen 2005 Trial participants not all within review inclusion criteria.
Quist-Paulsen 2003 Intervention conducted principally in hospital and out-patient clinics rather than primary care
Sheps 2004 Case-control study.
Southard 2003 Study duration/follow up six months. Trial participants not all within review inclusion criteria
van der Elst 2006 No randomisation.
Vlek 2003 Outcomes not those included in review.
Wood 2008 Trial participants in the primary care arm were not within review inclusion criteria
Wyer 2001 Outcomes not those included in review.
Young 2003 Outcomes not those included in review.
Zuckerman 2004 Not a randomised trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Service organisation versus normal care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Blood pressure within study
protocol target level at 12
months
3 3126 Odds Ratio (M-H, Random, 95% CI) 1.77 [1.00, 3.16]
2 Blood pressure within study
protocol target level at end of
study (per protocol)
4 3614 Odds Ratio (M-H, Random, 95% CI) 1.50 [0.96, 2.35]
3 Mean systolic blood pressure at
18 months
3 646 Mean Difference (IV, Random, 95% CI) 3.11 [0.04, 6.19]
4 Mean diastolic blood pressure at
18 months
3 691 Mean Difference (IV, Random, 95% CI) 1.00 [-0.66, 2.66]
5 Mean systolic blood pressure at
end of study (per protocol)
5 1722 Mean Difference (IV, Random, 95% CI) 1.55 [-0.35, 3.46]
6 Mean diastolic blood pressure at
end of study (per protocol)
5 1767 Mean Difference (IV, Random, 95% CI) 0.70 [-0.35, 1.76]
7 Total blood cholesterol within
study protocol target level (5.2
mmol/l) at 12 months
2 1685 Odds Ratio (M-H, Random, 95% CI) 1.90 [1.04, 3.48]
8 Total blood cholesterol within
study protocol target level at
end of study
3 2173 Odds Ratio (M-H, Random, 95% CI) 1.37 [0.63, 3.01]
9 Total blood cholesterol at end of
study (per protocol)
4 1410 Mean Difference (IV, Random, 95% CI) 0.06 [-0.05, 0.17]
10 Prescribed lipid-lowering
medication at 18 months
3 776 Odds Ratio (M-H, Random, 95% CI) 1.10 [0.76, 1.61]
11 Prescribed lipid-lowering
medication at end of study
6 2138 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.79, 1.19]
12 Prescribed beta blockers at end
of study
3 1650 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.67, 1.10]
13 Prescribed ACE inhibitors at
end of study
2 655 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.63, 1.18]
14 Prescribed anti-platelet
medication at 18 months
3 844 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.60, 1.58]
15 Prescribed anti-platelet
medication at end of study
6 5347 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.86, 1.57]
16 Exercising at or above study
target level at end of study
3 3112 Odds Ratio (M-H, Random, 95% CI) 1.11 [0.95, 1.29]
17 Smoking cessation at end of
study
3 3272 Odds Ratio (M-H, Random, 95% CI) 1.06 [0.89, 1.25]
18 Body mass index at end of
study
3 1414 Mean Difference (IV, Random, 95% CI) 0.25 [-0.28, 0.78]
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Analysis 1.1. Comparison 1 Service organisation versus normal care, Outcome 1 Blood pressure within
study protocol target level at 12 months.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 1 Blood pressure within study protocol target level at 12 months
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bond 2007b 218/500 421/941 37.0 % 1.05 [ 0.84, 1.30 ]
Campbell 1998 510/670 572/673 35.8 % 1.78 [ 1.35, 2.34 ]
Gao 2007 116/159 166/183 27.2 % 3.62 [ 1.97, 6.66 ]
Total (95% CI) 1329 1797 100.0 % 1.77 [ 1.00, 3.16 ]
Total events: 844 (Control), 1159 (Intervention)
Heterogeneity: Tau2 = 0.22; Chi2 = 18.96, df = 2 (P = 0.00008); I2 =89%
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.2. Comparison 1 Service organisation versus normal care, Outcome 2 Blood pressure within
study protocol target level at end of study (per protocol).
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 2 Blood pressure within study protocol target level at end of study (per protocol)
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bond 2007b 218/500 421/941 28.2 % 1.05 [ 0.84, 1.30 ]
Campbell 1998 510/670 572/673 27.1 % 1.78 [ 1.35, 2.34 ]
Gao 2007 116/159 166/183 19.3 % 3.62 [ 1.97, 6.66 ]
SPHERE 147/249 139/239 25.3 % 0.96 [ 0.67, 1.38 ]
Total (95% CI) 1578 2036 100.0 % 1.50 [ 0.96, 2.35 ]
Total events: 991 (Control), 1298 (Intervention)
Heterogeneity: Tau2 = 0.17; Chi2 = 22.16, df = 3 (P = 0.00006); I2 =86%
Test for overall effect: Z = 1.80 (P = 0.072)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Service organisation versus normal care, Outcome 3 Mean systolic blood
pressure at 18 months.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 3 Mean systolic blood pressure at 18 months
Study or subgroup Control Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moher 2001a (GP led) 36 148.1 (22.3) 85 147.1 (21.5) 12.8 % 1.00 [ -7.60, 9.60 ]
Moher 2001b (nurse led) 37 148.1 (22.3) 93 148.4 (21.5) 13.4 % -0.30 [ -8.71, 8.11 ]
SPHERE 209 137.9 (19.3) 186 133.8 (17) 73.8 % 4.10 [ 0.52, 7.68 ]
Total (95% CI) 282 364 100.0 % 3.11 [ 0.04, 6.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Service organisation versus normal care, Outcome 4 Mean diastolic blood
pressure at 18 months.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 4 Mean diastolic blood pressure at 18 months
Study or subgroup Control Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moher 2001a (GP led) 36 80.6 (12.4) 85 80.6 (10.6) 12.8 % 0.0 [ -4.64, 4.64 ]
Moher 2001b (nurse led) 37 80.6 (12.4) 93 79.8 (12.3) 12.4 % 0.80 [ -3.91, 5.51 ]
SPHERE 233 78.6 (10.4) 207 77.4 (10.1) 74.8 % 1.20 [ -0.72, 3.12 ]
Total (95% CI) 306 385 100.0 % 1.00 [ -0.66, 2.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Service organisation versus normal care, Outcome 5 Mean systolic blood
pressure at end of study (per protocol).
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 5 Mean systolic blood pressure at end of study (per protocol)
Study or subgroup Control Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cupples 1994a 300 136 (21.52) 317 136.5 (20.54) 32.9 % -0.50 [ -3.82, 2.82 ]
Moher 2001a (GP led) 73 148.1 (22.3) 85 147.1 (21.5) 7.7 % 1.00 [ -5.86, 7.86 ]
Moher 2001b (nurse led) 74 148.1 (22) 92 148.4 (21.5) 8.2 % -0.30 [ -6.97, 6.37 ]
SHIP 1999 205 139.1 (20.5) 181 136.9 (19.4) 22.9 % 2.20 [ -1.78, 6.18 ]
SPHERE 209 137.9 (19.3) 186 133.8 (17) 28.3 % 4.10 [ 0.52, 7.68 ]
Total (95% CI) 861 861 100.0 % 1.55 [ -0.35, 3.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.83, df = 4 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Service organisation versus normal care, Outcome 6 Mean diastolic blood
pressure at end of study (per protocol).
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 6 Mean diastolic blood pressure at end of study (per protocol)
Study or subgroup Control Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cupples 1994a 300 77 (12.23) 317 76.9 (10.33) 34.7 % 0.10 [ -1.69, 1.89 ]
Moher 2001a (GP led) 73 80.6 (12.4) 85 80.6 (10.6) 8.5 % 0.0 [ -3.63, 3.63 ]
Moher 2001b (nurse led) 74 80.6 (12.4) 92 79.8 (12.3) 7.8 % 0.80 [ -2.98, 4.58 ]
SHIP 1999 205 85 (12.2) 181 83.7 (12.2) 18.7 % 1.30 [ -1.14, 3.74 ]
SPHERE 233 78.6 (10.4) 207 77.4 (10.1) 30.3 % 1.20 [ -0.72, 3.12 ]
Total (95% CI) 885 882 100.0 % 0.70 [ -0.35, 1.76 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.07, df = 4 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Service organisation versus normal care, Outcome 7 Total blood cholesterol
within study protocol target level (5.2 mmol/l) at 12 months.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 7 Total blood cholesterol within study protocol target level (5.2 mmol/l) at 12 months
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Campbell 1998 125/670 244/673 57.3 % 2.48 [ 1.93, 3.18 ]
Gao 2007 123/159 150/183 42.7 % 1.33 [ 0.78, 2.26 ]
Total (95% CI) 829 856 100.0 % 1.90 [ 1.04, 3.48 ]
Total events: 248 (Control), 394 (Intervention)
Heterogeneity: Tau2 = 0.15; Chi2 = 4.35, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 2.09 (P = 0.037)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Service organisation versus normal care, Outcome 8 Total blood cholesterol
within study protocol target level at end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 8 Total blood cholesterol within study protocol target level at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Campbell 1998 125/670 244/673 35.2 % 2.48 [ 1.93, 3.18 ]
Gao 2007 123/159 150/183 31.3 % 1.33 [ 0.78, 2.26 ]
SPHERE 180/249 159/239 33.5 % 0.76 [ 0.52, 1.12 ]
Total (95% CI) 1078 1095 100.0 % 1.37 [ 0.63, 3.01 ]
Total events: 428 (Control), 553 (Intervention)
Heterogeneity: Tau2 = 0.44; Chi2 = 26.17, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.9. Comparison 1 Service organisation versus normal care, Outcome 9 Total blood cholesterol at
end of study (per protocol).
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 9 Total blood cholesterol at end of study (per protocol)
Study or subgroup Control Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cupples 1994a 285 6.08 (1.09) 313 6.05 (1.07) 38.2 % 0.03 [ -0.14, 0.20 ]
Kiessling 2002 30 6.3 (0.9) 33 5.8 (1.3) 4.0 % 0.50 [ -0.05, 1.05 ]
SHIP 1999 205 5.9 (1.1) 181 5.8 (1.1) 24.3 % 0.10 [ -0.12, 0.32 ]
SPHERE 194 4.2 (0.9) 169 4.2 (0.9) 33.5 % 0.0 [ -0.19, 0.19 ]
Total (95% CI) 714 696 100.0 % 0.06 [ -0.05, 0.17 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.11, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Service organisation versus normal care, Outcome 10 Prescribed lipid-
lowering medication at 18 months.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 10 Prescribed lipid-lowering medication at 18 months
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moher 2001a (GP led) 19/52 52/126 32.1 % 1.22 [ 0.63, 2.38 ]
Moher 2001b (nurse led) 20/53 51/125 32.8 % 1.14 [ 0.59, 2.20 ]
SPHERE 200/222 178/198 35.1 % 0.98 [ 0.52, 1.85 ]
Total (95% CI) 327 449 100.0 % 1.10 [ 0.76, 1.61 ]
Total events: 239 (Control), 281 (Intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Service organisation versus normal care, Outcome 11 Prescribed lipid-
lowering medication at end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 11 Prescribed lipid-lowering medication at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eccles 2002 189/506 172/488 48.3 % 0.91 [ 0.70, 1.18 ]
Feder 1999 13/67 19/65 6.2 % 1.72 [ 0.77, 3.85 ]
Moher 2001a (GP led) 19/52 52/126 8.9 % 1.22 [ 0.63, 2.38 ]
Moher 2001b (nurse led) 20/53 51/125 9.1 % 1.14 [ 0.59, 2.20 ]
Munoz 2007 66/85 68/83 7.0 % 1.31 [ 0.61, 2.78 ]
SPHERE 200/249 178/239 20.6 % 0.71 [ 0.47, 1.10 ]
Total (95% CI) 1012 1126 100.0 % 0.97 [ 0.79, 1.19 ]
Total events: 507 (Control), 540 (Intervention)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.35, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Service organisation versus normal care, Outcome 12 Prescribed beta
blockers at end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 12 Prescribed beta blockers at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eccles 2002 248/506 236/488 52.2 % 0.97 [ 0.76, 1.25 ]
Munoz 2007 40/85 38/83 14.4 % 0.95 [ 0.52, 1.74 ]
SPHERE 144/249 115/239 33.4 % 0.68 [ 0.47, 0.97 ]
Total (95% CI) 840 810 100.0 % 0.86 [ 0.67, 1.10 ]
Total events: 432 (Control), 389 (Intervention)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.78, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Service organisation versus normal care, Outcome 13 Prescribed ACE
inhibitors at end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 13 Prescribed ACE inhibitors at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Munoz 2007 35/85 27/82 24.9 % 0.70 [ 0.37, 1.32 ]
SPHERE 101/249 92/239 75.1 % 0.92 [ 0.64, 1.32 ]
Total (95% CI) 334 321 100.0 % 0.86 [ 0.63, 1.18 ]
Total events: 136 (Control), 119 (Intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Service organisation versus normal care, Outcome 14 Prescribed anti-platelet
medication at 18 months.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 14 Prescribed anti-platelet medication at 18 months
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moher 2001a (GP led) 37/52 93/126 27.3 % 1.14 [ 0.56, 2.35 ]
Moher 2001b (nurse led) 38/53 99/125 26.5 % 1.50 [ 0.72, 3.14 ]
SPHERE 195/249 171/239 46.2 % 0.70 [ 0.46, 1.05 ]
Total (95% CI) 354 490 100.0 % 0.98 [ 0.60, 1.58 ]
Total events: 270 (Control), 363 (Intervention)
Heterogeneity: Tau2 = 0.09; Chi2 = 3.77, df = 2 (P = 0.15); I2 =47%
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Service organisation versus normal care, Outcome 15 Prescribed anti-platelet
medication at end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 15 Prescribed anti-platelet medication at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bond 2007b 435/500 812/941 18.5 % 0.94 [ 0.68, 1.30 ]
Campbell 1998 373/670 466/673 20.6 % 1.79 [ 1.43, 2.24 ]
Moher 2001a (GP led) 199/280 502/682 18.7 % 1.14 [ 0.83, 1.55 ]
Moher 2001b (nurse led) 199/280 524/665 18.5 % 1.51 [ 1.10, 2.08 ]
Munoz 2007 75/85 73/83 7.3 % 0.97 [ 0.38, 2.48 ]
SPHERE 195/249 171/239 16.3 % 0.70 [ 0.46, 1.05 ]
Total (95% CI) 2064 3283 100.0 % 1.16 [ 0.86, 1.57 ]
Total events: 1476 (Control), 2548 (Intervention)
Heterogeneity: Tau2 = 0.10; Chi2 = 22.61, df = 5 (P = 0.00040); I2 =78%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Service organisation versus normal care, Outcome 16 Exercising at or above
study target level at end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 16 Exercising at or above study target level at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bond 2007b 140/500 282/941 40.8 % 1.10 [ 0.87, 1.40 ]
Campbell 1998 177/510 247/673 40.6 % 1.09 [ 0.86, 1.39 ]
SPHERE 116/249 121/239 18.6 % 1.18 [ 0.82, 1.68 ]
Total (95% CI) 1259 1853 100.0 % 1.11 [ 0.95, 1.29 ]
Total events: 433 (Control), 650 (Intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Service organisation versus normal care, Outcome 17 Smoking cessation at
end of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 17 Smoking cessation at end of study
Study or subgroup Control Intervention
Odds
Ratio(Non-
event) Weight
Odds
Ratio(Non-
event)
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bond 2007b 417/500 807/941 31.8 % 1.20 [ 0.89, 1.62 ]
Campbell 1998 481/670 483/673 50.0 % 1.00 [ 0.79, 1.27 ]
SPHERE 179/249 171/239 18.2 % 0.98 [ 0.66, 1.46 ]
Total (95% CI) 1419 1853 100.0 % 1.06 [ 0.89, 1.25 ]
Total events: 1077 (Control), 1461 (Intervention)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Service organisation versus normal care, Outcome 18 Body mass index at end
of study.
Review: Service organisation for the secondary prevention of ischaemic heart disease in primary care
Comparison: 1 Service organisation versus normal care
Outcome: 18 Body mass index at end of study
Study or subgroup Control Intervention
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cupples 1994a 300 26.8 (4.67) 317 26.76 (4.59) 52.2 % 0.04 [ -0.69, 0.77 ]
SHIP 1999 205 28.2 (8.3) 181 27.4 (4.1) 16.9 % 0.80 [ -0.48, 2.08 ]
SPHERE 219 28.7 (4.8) 192 28.4 (5) 30.9 % 0.30 [ -0.65, 1.25 ]
Total (95% CI) 724 690 100.0 % 0.25 [ -0.28, 0.78 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Table of included studies
Study Setting Study partici-
pant recruitment
criteria
Number and sex
of participants
Mean age of par-
tici-
pants (SD unless
stated otherwise)
Elements in-
cluded in inter-
vention (see key
in footnotes)
Study length
(months)
Bond 2007b England Previous AMI,
CABG, PTCA,
diagnosed
angina
1,441 (68%
male)
Control: 68.8 (9.
1)
Intervention: 68.
7 (9.2)
1,2,3,4,8 12
Campbell 1998 Scotland Pre-
vious AMI, diag-
nosed angina
1,343 (58%
male)
Control: 66.3 (8.
2)
Intervention: 66.
1 (8.2)
1,2,3,4,7 12
Cupples 1994a Northern
Ireland
Pre-
vious AMI, diag-
nosed angina
688 (59% male) Control: 63.6 (6.
8)
Intervention: 62.
7 (7.1)
2,3,7 24
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Table 1. Table of included studies (Continued)
Eccles 2002 England Diagnosed
angina
2,881
Men & women
18+ 4,6 12
Feder 1999 England Pre-
vious AMI, diag-
nosed angina
328 (59% male) Control: 64.8
Intervention: 66.
4
3,4 12
Gao 2007 China Previous CABG 368 (68% male) Total: 62 (±11) 1,2,3,5 12
SHIP 1999 England Pre-
vious AMI, diag-
nosed angina
597 (71% male) Control: 64 (10)
Intervention: 63
(10)
2,4,5,7 12
Kiessling 2002 Sweden Previous AMI,
CABG, PTCA,
diagnosed
angina
88 (85% male) Control: 62.3 (7.
4)
Intervention: 62.
6 (6.1)
4 24
Moher 2001a
(GP led)
England Previous AMI,
CABG, PTCA,
diagnosed
angina
1,241 (67%
male)
Control: 66.1 (5.
4)
Intervention: 66.
4 (5.6)
2,4 18
Moher 2001b
(nurse led)
England Previous AMI,
CABG, PTCA,
diagnosed
angina
1,224 (69%
male)
Control: 66.1 (5.
4)
Intervention: 65.
8 (5.8)
2,4,7 18
Munoz 2007 Spain Pre-
vious AMI, diag-
nosed angina
983 (75% male) Control: 63.6
(10.3)
Intervention:64.
2 (9.8)
1,2,3,4 36
SPHERE Republic of Ire-
land and North-
ern Ireland
Previous AMI,
CABG, PTCA,
diagnosed
angina
892 (70% male) Control: 66.5 (9.
9)
Intervention: 68.
5 (9.3)
1,2,3,4,7 18
Elements of interventions:
1. Structured monitoring and assessment of risk factors and medications
2. Preplanned appointment/s / patient recall
3. Patient education or awareness raising regarding secondary prevention: risk factors, medications and lifestyle
4. Clinician education or awareness raising regarding secondary prevention: promotion of clinical guidelines, clinical management
advice, education or training
5. Improved secondary/primary care interface
6. Information technology based decision supports
7. Nurse proactive in care management
8. Pharmacist proactive in care management
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A P P E N D I C E S
Appendix 1. Search strategies
Search strategy for CENTRAL on The Cochrane Library
#1 MeSH descriptor myocardial ischemia explode all trees
#2 MeSH descriptor Heart diseases this term only
#3 MeSH descriptor myocardial revascularization explode all trees
#4 angina
#5 (heart near/3 disease* )
#6 (coronary near/3 disease* )
#7 myocardial next infarct*
#8 (coronary near/3 bypass* )
#9 cabg
#10 (coronary near/3 angioplast* )
#11 ptca
#12 (heart near/3 infarct* )
#13 postmyocardial
#14 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13)
#15 MeSH descriptor Delivery of Health Care this term only
#16 MeSH descriptor patient care management this term only
#17 MeSH descriptor comprehensive health care this term only
#18 MeSH descriptor nursing process this term only
#19 MeSH descriptor nursing assessment explode all trees
#20 MeSH descriptor patient care planning explode all trees
#21 MeSH descriptor patient-centered care this term only
#22 MeSH descriptor Delivery of health care this term only
#23 MeSH descriptor Delivery of Health Care, Integrated this term only
#24 MeSH descriptor managed care programs explode all trees
#25 MeSH descriptor disease management this term only
#26 MeSH descriptor patient care team explode all trees
#27 MeSH descriptor Physician’s Practice Patterns explode all trees
#28 MeSH descriptor primary health care explode all trees
#29 MeSH descriptor Physicians, Family this term only
#30 MeSH descriptor family practice this term only
#31 MeSH descriptor reminder systems this term only
#32 MeSH descriptor communication explode all trees
#33 MeSH descriptor guideline adherence this term only
#34 MeSH descriptor home care services this term only
#35 MeSH descriptor home nursing this term only
#36 MeSH descriptor ambulatory care this term only
#37 MeSH descriptor patient discharge this term only
#38 aftercare
#39 (manag* near/3 care )
#40 (service* near/3 reorgani* )
#41 (organis* near/2 service* )
#42 (organiz* near/3 service* )
#43 (manag* near/3 program* )
#44 (case* near/3 manag* )
#45 (patient* near/3 manag* )
#46 (home near/3 intervention* )
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#47 (home near/3 care )
#48 (home near/3 visit* )
#49 MeSH descriptor Nurse’s Role this term only
#50 MeSH descriptor Nurse Practitioners this term only
#51 MeSH descriptor Ambulatory Care this term only
#52 (discharg* near/3 plan* )
#53 (comprehensiv* near/3 care )
#54 (treatment* near/3 plan* )
#55 (nurse* near/3 led )
#56 (disease near/3 manag* )
#57 multidisciplin*
#58 multi-disciplin*
#59 (#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24)
#60 (#25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34)
#61 (#35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44)
#62 (#45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54)
#63 (#55 or #56 or #57 or #58)
#64 (#59 or #60 or #61 or #62 or #63)
#65 (#14 and #64)
#66 MeSH descriptor Community Health Services this term only
#67 MeSH descriptor medical audit this term only
#68 MeSH descriptor nursing audit this term only
#69 audit
#70 secondary next prevention next clinic*
#71 general next practi*
#72 primary next care
#73 reminder*
#74 family next practi*
#75 recall*
#76 (nurse near/3 clinic* )
#77 (secondary next prevention near/3 intervention* )
#78 (secondary next prevention near/3 program* )
#79 MeSH descriptor Appointments and Schedules this term only
#80 appointment*
#81 (#66 or #67 or #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75)
#82 (#76 or #77 or #78 or #79 or #80)
#83 (#81 or #82)
#84 (#83 and #14)
#85 (#65 or #84)
Search strategy for MEDLINE (on Ovid)
1. exp Myocardial Ischemia/ (277135)
2. Heart Diseases/ (44292)
3. angina.tw. (35108)
4. (heart adj3 disease$).tw. (91336)
5. (coronary adj3 disease$).tw. (74985)
6. myocardial infarct$.tw. (101926)
7. exp Myocardial Revascularization/ (57078)
8. (coronary adj3 bypass$).tw. (26367)
9. cabg.tw. (7654)
10. (coronary adj3 angioplast$).tw. (12088)
11. ptca.tw. (5750)
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12. (heart adj3 infarct$).tw. (3806)
13. postmyocardial infarct$.tw. (649)
14. or/1-13 (407492)
15. “Delivery of Health Care”/ (45899)
16. patient care management/ (1322)
17. comprehensive health care/ (5472)
18. nursing process/ (5733)
19. exp nursing assessment/ (25136)
20. exp patient care planning/ (40802)
21. Patient-Centered Care/ (4741)
22. delivery of health care/ (45899)
23. “Delivery of Health Care, Integrated”/ (5242)
24. exp managed care programs/ (36394)
25. disease management/ (5717)
26. exp patient care team/ (40297)
27. exp Primary Health Care/ (50165)
28. Physicians, Family/ (11503)
29. Family Practice/ (52241)
30. Reminder Systems/ (1155)
31. interdisciplinary communication/ (3050)
32. Guideline Adherence/ (9335)
33. or/15-32 (293796)
34. 14 and 33 (5861)
35. “Continuity of Patient Care”/ (9267)
36. home care services/ (22192)
37. home nursing/ (7063)
38. ambulatory care/ (28931)
39. patient discharge/ (12740)
40. (manag$ adj3 care).tw. (24362)
41. (management adj3 program$).tw. (6612)
42. (case adj3 manag$).tw. (8628)
43. (patient adj3 management).tw. (13720)
44. (home adj3 intervention$).tw. (792)
45. (home adj3 care).tw. (14487)
46. (home adj visit$).tw. (3134)
47. (ambulatory adj care).tw. (4940)
48. (discharg$ adj3 program$).tw. (435)
49. (practice adj guideline).tw. (1275)
50. (discharg$ adj3 planning).tw. (1677)
51. (comprehensive adj3 care).tw. (3818)
52. (treatment adj3 plan$).tw. (23753)
53. (nurse$ adj3 led).tw. (964)
54. (disease adj management).tw. (3751)
55. multi-disciplin$.tw. (1647)
56. multidisciplin$.tw. (21674)
57. or/35-56 (184085)
58. 57 and 14 (5427)
59. 58 or 34 (10157)
60. exp Communication/ (248933)
61. (service$ adj3 organi$).tw. (3690)
62. Nurse’s Role/ (19899)
63. Nurse Practitioners/ (11946)
64. Ambulatory Care/ (28931)
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65. (nurse adj3 led).tw. (885)
66. Community Health Services/ (21716)
67. Medical Audit/ (10870)
68. Nursing Audit/ (2576)
69. audit.tw. (13592)
70. secondary prevention clinic$.tw. (26)
71. general practi$.tw. (43177)
72. primary care.tw. (39512)
73. reminder$.tw. (3724)
74. family practi$.tw. (6988)
75. recall$.tw. (28298)
76. (nurse adj3 clinic$).tw. (3232)
77. (secondary prevention adj3 intervention$).tw. (117)
78. (secondary prevention adj3 program$).tw. (254)
79. “Appointments and Schedules”/ (5345)
80. appointment$.tw. (7595)
81. or/61-80 (221704)
82. 14 and 81 (6357)
83. 34 or 58 or 82 (13358)
84. randomized controlled trial.pt. (247715)
85. controlled clinical trial.pt. (76282)
86. Randomized controlled trials/ (52178)
87. random allocation/ (59563)
88. double blind method/ (94539)
89. single-blind method/ (11596)
90. or/84-89 (418117)
91. exp animal/ not humans/ (3249906)
92. 90 not 91 (391765)
93. clinical trial.pt. (440338)
94. exp Clinical Trials as Topic/ (197765)
95. (clin$ adj25 trial$).ti,ab. (139930)
96. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).ti,ab. (91248)
97. random$.ti,ab. (395118)
98. research design/ (50847)
99. or/93-98 (870162)
100. 99 and 83 (2121)
Search strategy for EMBASE (on Ovid)
1. exp Ischemic heart disease/ (214206)
2. Heart Diseases/ (26652)
3. angina.tw. (28660)
4. (heart adj3 disease$).tw. (68501)
5. (coronary adj3 disease$).tw. (66280)
6. myocardial infarct$.tw. (79601)
7. exp Myocardial Revascularization/ (10813)
8. (coronary adj3 bypass$).tw. (23578)
9. cabg.tw. (7054)
10. (coronary adj3 angioplast$).tw. (11363)
11. ptca.tw. (5472)
12. heart infarct$.tw. (763)
13. postmyocardial infarct$.tw. (534)
14. or/1-13 (310571)
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15. “Delivery of Health Care”/ (36976)
16. nursing process/ (13)
17. nursing assessment/ (28)
18. patient care planning/ (289)
19. “Integrated Health Care System”/ (182)
20. disease management/ (881)
21. case management/ (365)
22. exp Primary Health Care/ (38904)
23. Family Practitioner/ (28102)
24. General Practice/ (21435)
25. Reminder System/ (131)
26. interdisciplinary communication/ (723)
27. or/15-26 (108608)
28. 14 and 27 (4111)
29. ambulatory care/ (6547)
30. (manag$ adj3 care).tw. (14157)
31. (management adj3 program$).tw. (5112)
32. (case adj3 manag$).tw. (5711)
33. (patient adj3 management).tw. (11976)
34. (home adj3 intervention$).tw. (640)
35. (home adj3 care).tw. (5995)
36. (home adj visit$).tw. (2073)
37. (ambulatory adj care).tw. (2858)
38. (discharg$ adj3 program$).tw. (334)
39. (practice adj guideline).tw. (994)
40. (discharg$ adj3 planning).tw. (668)
41. (comprehensive adj3 care).tw. (2279)
42. (treatment adj3 plan$).tw. (22951)
43. (nurse$ adj3 led).tw. (494)
44. (disease adj management).tw. (3290)
45. multi-disciplin$.tw. (1552)
46. multidisciplin$.tw. (18907)
47. or/29-46 (96963)
48. 47 and 14 (3285)
49. (service$ adj3 organi$).tw. (2006)
50. Nurse Practitioner/ (1862)
51. Ambulatory Care/ (6547)
52. (nurse adj3 led).tw. (468)
53. Community Care/ (16903)
54. Medical Audit/ (11229)
55. Nursing Audit/ (11607)
56. audit.tw. (11516)
57. secondary prevention clinic$.tw. (28)
58. general practi$.tw. (32763)
59. primary care.tw. (32166)
60. reminder$.tw. (2829)
61. family practi$.tw. (4405)
62. recall$.tw. (21827)
63. (nurse adj3 clinic$).tw. (831)
64. (secondary prevention adj3 intervention$).tw. (119)
65. (secondary prevention adj3 program$).tw. (211)
66. appointment$.tw. (4914)
67. or/49-66 (140039)
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68. 14 and 67 (5281)
69. 28 or 48 or 68 (9709)
70. random$.ti,ab. (360908)
71. factorial$.ti,ab. (7393)
72. (crossover$ or cross over$ or cross-over$).ti,ab. (37365)
73. (double$ adj blind$).ti,ab. (80760)
74. (singl$ adj blind$).ti,ab. (7017)
75. assign$.ti,ab. (100633)
76. allocat$.ti,ab. (31580)
77. volunteer$.ti,ab. (93637)
78. Crossover Procedure/ (19892)
79. Double Blind Procedure/ (68037)
80. Randomized Controlled Trial/ (153884)
81. Single Blind Procedure/ (7329)
82. or/70-81 (588428)
83. 69 and 82 (1358)
Search strategy for CINAHL (on EBSCO)
( (MH “Myocardial Ischemia+”) or heart disease or coronary ) and ( (MH “Case Management”) or (MH “Disease Management”) or
(MH “Family Practice”) or (MH “Primary Health Care”) or disease management or multidisciplinary or nurse led or primary care or
general practice ) and ( (MH “Clinical Trials”) or random* or clinical trial )
WH A T ’ S N E W
Last assessed as up-to-date: 20 August 2008.
Date Event Description
4 April 2013 Review declared as stable Authors are unable to update this review.
C O N T R I B U T I O N S O F A U T H O R S
Brian Buckley is the lead author and is principally responsible for the conception and design of the study. He wrote the protocol,
incorporating comments from co-reviewers, selected studies according to the criteria, led the analysis and interpretation of the data and
drafted the final review.
Mary Byrne selected studies according to the criteria, contributed to the revision of the review.
Susan Smith contributed to the design of the study, the preparation of the protocol and the revision of the review.
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D E C L A R A T I O N S O F I N T E R E S T
Mary Byrne and Susan Smith were investigators on the SPHERE study, which was completed before the search and included in the
review.
S O U R C E S O F S U P P O R T
Internal sources
• Department of General Practice, National University of Ireland, Galway, Ireland.
• Department of Public Health and Primary Care, Trinity College, Dublin, Ireland.
External sources
• Health Research Board Cochrane Fellowship, Ireland.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The term “primary care” has been added to the title to make more explicit the scope of the review.
It became clear during the study selection phase that some thought had to be given to length of follow up. The nature of the interventions
meant that they were often lengthy and ongoing in nature. The length of follow up was hard to determine in some cases in that
the activities or elements of care which constituted the intervention could not easily be withdrawn from patients or the education or
guidelines provided to clinicians could not be undone. Thus the authors determined that a twelve month “length of study” would be
acceptable as minimum “length of follow up”.
N O T E S
Authors are unable to update this review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Myocardial Ischemia [∗prevention & control]; Patient Compliance; Primary Health Care [organization & administration]; Secondary
Prevention [∗organization & administration]
MeSH check words
Humans
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